WO2019080723A1 - Dérivé de pyridone polysubstitué, son procédé de préparation et son utilisation médicale - Google Patents
Dérivé de pyridone polysubstitué, son procédé de préparation et son utilisation médicaleInfo
- Publication number
- WO2019080723A1 WO2019080723A1 PCT/CN2018/109969 CN2018109969W WO2019080723A1 WO 2019080723 A1 WO2019080723 A1 WO 2019080723A1 CN 2018109969 W CN2018109969 W CN 2018109969W WO 2019080723 A1 WO2019080723 A1 WO 2019080723A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- cycloalkyl
- alkyl
- cancer
- aryl
- Prior art date
Links
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 302
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 239000003112 inhibitor Substances 0.000 claims abstract description 8
- -1 amino, nitro, cyano, hydroxy, decyl Chemical group 0.000 claims description 229
- 125000000623 heterocyclic group Chemical group 0.000 claims description 210
- 125000000217 alkyl group Chemical group 0.000 claims description 174
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 174
- 239000000203 mixture Substances 0.000 claims description 174
- 125000003118 aryl group Chemical group 0.000 claims description 168
- 125000001072 heteroaryl group Chemical group 0.000 claims description 164
- 150000001875 compounds Chemical class 0.000 claims description 156
- 229910052736 halogen Inorganic materials 0.000 claims description 97
- 150000002367 halogens Chemical group 0.000 claims description 96
- 125000003545 alkoxy group Chemical group 0.000 claims description 85
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 79
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 75
- 125000004043 oxo group Chemical group O=* 0.000 claims description 70
- 150000002148 esters Chemical group 0.000 claims description 64
- 125000000304 alkynyl group Chemical group 0.000 claims description 61
- 150000003839 salts Chemical class 0.000 claims description 61
- 125000003342 alkenyl group Chemical group 0.000 claims description 54
- 229910052757 nitrogen Inorganic materials 0.000 claims description 53
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 48
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 34
- 229910020008 S(O) Inorganic materials 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 22
- 125000004185 ester group Chemical group 0.000 claims description 22
- 201000005202 lung cancer Diseases 0.000 claims description 22
- 208000020816 lung neoplasm Diseases 0.000 claims description 22
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 22
- 201000005787 hematologic cancer Diseases 0.000 claims description 21
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 21
- 206010006187 Breast cancer Diseases 0.000 claims description 20
- 208000026310 Breast neoplasm Diseases 0.000 claims description 20
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 20
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 20
- 206010017758 gastric cancer Diseases 0.000 claims description 20
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 20
- 201000002528 pancreatic cancer Diseases 0.000 claims description 20
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 20
- 201000011549 stomach cancer Diseases 0.000 claims description 20
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 17
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 229910052721 tungsten Inorganic materials 0.000 claims description 11
- 229910052720 vanadium Inorganic materials 0.000 claims description 11
- 206010005003 Bladder cancer Diseases 0.000 claims description 10
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 10
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 10
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 10
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 10
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 10
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 10
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 10
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 10
- 206010038389 Renal cancer Diseases 0.000 claims description 10
- 206010039491 Sarcoma Diseases 0.000 claims description 10
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 10
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 10
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 10
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 10
- 201000010881 cervical cancer Diseases 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 201000004101 esophageal cancer Diseases 0.000 claims description 10
- 201000010536 head and neck cancer Diseases 0.000 claims description 10
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 10
- 201000002313 intestinal cancer Diseases 0.000 claims description 10
- 201000010982 kidney cancer Diseases 0.000 claims description 10
- 201000007270 liver cancer Diseases 0.000 claims description 10
- 208000014018 liver neoplasm Diseases 0.000 claims description 10
- 206010038038 rectal cancer Diseases 0.000 claims description 10
- 201000001275 rectum cancer Diseases 0.000 claims description 10
- 201000000849 skin cancer Diseases 0.000 claims description 10
- 201000002510 thyroid cancer Diseases 0.000 claims description 10
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 10
- 238000007112 amidation reaction Methods 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 238000010931 ester hydrolysis Methods 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 238000005809 transesterification reaction Methods 0.000 claims description 3
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 355
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 219
- 239000007787 solid Substances 0.000 description 217
- 238000006243 chemical reaction Methods 0.000 description 180
- 235000019439 ethyl acetate Nutrition 0.000 description 169
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 163
- 210000004027 cell Anatomy 0.000 description 95
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 92
- 238000005481 NMR spectroscopy Methods 0.000 description 92
- 238000000034 method Methods 0.000 description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 68
- 239000000543 intermediate Substances 0.000 description 62
- 239000011541 reaction mixture Substances 0.000 description 57
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 50
- 238000010898 silica gel chromatography Methods 0.000 description 49
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 47
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 47
- 239000012267 brine Substances 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 42
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 40
- 239000000243 solution Substances 0.000 description 40
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 38
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 38
- 230000002829 reductive effect Effects 0.000 description 36
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 35
- 239000012044 organic layer Substances 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 238000012360 testing method Methods 0.000 description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 27
- 239000003480 eluent Substances 0.000 description 27
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 26
- 235000019270 ammonium chloride Nutrition 0.000 description 25
- 239000000706 filtrate Substances 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 21
- 239000003921 oil Substances 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 20
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 20
- 229910000027 potassium carbonate Inorganic materials 0.000 description 20
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 19
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 19
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 19
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 18
- SIDZXXQYQLBOHZ-UHFFFAOYSA-N 4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluoroaniline Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC1=CC=C(N)C=C1F SIDZXXQYQLBOHZ-UHFFFAOYSA-N 0.000 description 17
- RNIVGJYWHHSMKA-UHFFFAOYSA-N diethyl 4-oxopyran-2,5-dicarboxylate Chemical compound CCOC(=O)C1=CC(=O)C(C(=O)OCC)=CO1 RNIVGJYWHHSMKA-UHFFFAOYSA-N 0.000 description 17
- 239000002609 medium Substances 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- MKJMTKSTMONLDG-UHFFFAOYSA-N 4H-pyrido[1,2-a]pyrazine-8-carboxamide Chemical compound C1=C2N(CC=N1)C=CC(=C2)C(=O)N MKJMTKSTMONLDG-UHFFFAOYSA-N 0.000 description 15
- BFICLMNNLSXLES-UHFFFAOYSA-N 6-ethoxycarbonyl-5-(4-fluorophenyl)-1-methyl-4-oxopyridine-3-carboxylic acid Chemical compound C(C)OC(=O)C1=C(C(C(=CN1C)C(=O)O)=O)C1=CC=C(C=C1)F BFICLMNNLSXLES-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 15
- 239000007821 HATU Substances 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 13
- 238000004587 chromatography analysis Methods 0.000 description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 13
- 125000006413 ring segment Chemical group 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000012091 fetal bovine serum Substances 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- ORPHLVJBJOCHBR-UHFFFAOYSA-N 403-19-0 Chemical compound OC1=CC=C([N+]([O-])=O)C=C1F ORPHLVJBJOCHBR-UHFFFAOYSA-N 0.000 description 11
- 125000002619 bicyclic group Chemical group 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 238000004113 cell culture Methods 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- QOLGFNPPWLWYKB-UHFFFAOYSA-N 10-(4-fluorophenyl)-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxylic acid Chemical compound C1COC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)O)C4=CC=C(C=C4)F QOLGFNPPWLWYKB-UHFFFAOYSA-N 0.000 description 10
- RUDFGVCQAZXNAJ-UHFFFAOYSA-N 3-(4-amino-2-fluorophenyl)-5-(3,4-dimethoxyphenyl)pyridin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C(N)C(C=2C(=CC(N)=CC=2)F)=C1 RUDFGVCQAZXNAJ-UHFFFAOYSA-N 0.000 description 10
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 125000003367 polycyclic group Chemical group 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- IQKDEFQVYLYAHD-UHFFFAOYSA-N 5-oxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide Chemical compound C1C2OC(=O)CN2CC2=CCC(C(=O)N)=CN21 IQKDEFQVYLYAHD-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 150000001408 amides Chemical class 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 9
- 238000012054 celltiter-glo Methods 0.000 description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 9
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 9
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 8
- SBAUKJHVFYEIPL-UHFFFAOYSA-N 11-(6-methylpyridin-3-yl)-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxylic acid Chemical compound CC1=CC=C(C=N1)C=1C(C(=CN2CC3OCCCN3C(C21)=O)C(=O)O)=O SBAUKJHVFYEIPL-UHFFFAOYSA-N 0.000 description 8
- NKTWEFPOIPLNLR-UHFFFAOYSA-N 3-(4-amino-2-fluorophenyl)-5-(1-ethylpyrazol-4-yl)pyridin-2-amine Chemical compound NC1=CC(=C(C=C1)C=1C(=NC=C(C=1)C=1C=NN(C=1)CC)N)F NKTWEFPOIPLNLR-UHFFFAOYSA-N 0.000 description 8
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 8
- XOYMXSWONJKENU-UHFFFAOYSA-N 6-(6,7-dimethoxyquinolin-4-yl)oxypyridazin-3-amine Chemical compound COc1cc2nccc(Oc3ccc(N)nn3)c2cc1OC XOYMXSWONJKENU-UHFFFAOYSA-N 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- WQZLUEWLCVCNGV-UHFFFAOYSA-N N-[4-[2-amino-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-3-yl]-3-fluorophenyl]-6-(azetidine-1-carbonyl)-5-(4-fluorophenyl)-1-methyl-4-oxopyridine-3-carboxamide Chemical compound NC1=NC=C(C=C1C1=C(C=C(C=C1)NC(=O)C1=CN(C(=C(C1=O)C1=CC=C(C=C1)F)C(=O)N1CCC1)C)F)C=1C=NN(C1)C1CCNCC1 WQZLUEWLCVCNGV-UHFFFAOYSA-N 0.000 description 8
- 125000003282 alkyl amino group Chemical group 0.000 description 8
- 150000004982 aromatic amines Chemical class 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 125000005366 cycloalkylthio group Chemical group 0.000 description 8
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 8
- 238000004949 mass spectrometry Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 7
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 7
- VZJWVVVRPJDHSZ-UHFFFAOYSA-N 3-fluoro-4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]oxyaniline Chemical compound C=12C=C(OC)C(OCCOC)=CC2=NC=NC=1OC1=CC=C(N)C=C1F VZJWVVVRPJDHSZ-UHFFFAOYSA-N 0.000 description 7
- IACVKAWALUBODZ-UHFFFAOYSA-N 4-[2-(4-bromo-2-methoxyphenoxy)ethoxymethyl]-2,2-dimethyl-1,3-dioxolane Chemical compound CC1(OCC(O1)COCCOC2=C(C=C(C=C2)Br)OC)C IACVKAWALUBODZ-UHFFFAOYSA-N 0.000 description 7
- FZRBMKFTDBVGRU-UHFFFAOYSA-N B(C1=CC(=CN=C1N)Br)(O)O Chemical compound B(C1=CC(=CN=C1N)Br)(O)O FZRBMKFTDBVGRU-UHFFFAOYSA-N 0.000 description 7
- 0 C=CN(*1)C(CCC2)C2NC1=O Chemical compound C=CN(*1)C(CCC2)C2NC1=O 0.000 description 7
- XASJRVNDSPQILZ-UHFFFAOYSA-N COC1=C(C=C2C(OC3=CC=C(N)C=C3F)=CC=NC2=C1)C(N)=O Chemical compound COC1=C(C=C2C(OC3=CC=C(N)C=C3F)=CC=NC2=C1)C(N)=O XASJRVNDSPQILZ-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000012295 chemical reaction liquid Substances 0.000 description 7
- 125000000000 cycloalkoxy group Chemical group 0.000 description 7
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 7
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- KXMZDGSRSGHMMK-VWLOTQADSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[(7s)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1([C@H]2CCC3=CC=C(C=C3CC2)NC=2N=C(N(N=2)C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)N)CCCC1 KXMZDGSRSGHMMK-VWLOTQADSA-N 0.000 description 6
- MHRMSZPCHBTAJN-UHFFFAOYSA-N 4-(2-fluoro-4-nitrophenoxy)-6,7-dimethoxyquinoline Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC1=CC=C([N+]([O-])=O)C=C1F MHRMSZPCHBTAJN-UHFFFAOYSA-N 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 6
- MYQFBYDORHDKPQ-UHFFFAOYSA-N 5-(4-fluorophenyl)-4-oxo-1-propan-2-ylpyridine-3-carboxylic acid Chemical compound CC(C)N1C=C(C(O)=O)C(=O)C(C=2C=CC(F)=CC=2)=C1 MYQFBYDORHDKPQ-UHFFFAOYSA-N 0.000 description 6
- KPNWZQGRIVUQPN-UHFFFAOYSA-N 5-bromo-6-ethoxycarbonyl-1-(oxan-4-ylmethyl)-4-oxopyridine-3-carboxylic acid Chemical compound CCOC(=O)C1=C(C(=O)C(=CN1CC2CCOCC2)C(=O)O)Br KPNWZQGRIVUQPN-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229950009568 bemcentinib Drugs 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 150000007942 carboxylates Chemical group 0.000 description 6
- ZLBYTNKVUGROJL-UHFFFAOYSA-N diethyl 3-bromo-1-methyl-4-oxopyridine-2,5-dicarboxylate Chemical compound C(C)OC(=O)C=1N(C=C(C(C1Br)=O)C(=O)OCC)C ZLBYTNKVUGROJL-UHFFFAOYSA-N 0.000 description 6
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 6
- LQSOVGAUOHMPLK-VURMDHGXSA-N ethyl (2z)-2-(dimethylaminomethylidene)-3-oxobutanoate Chemical compound CCOC(=O)C(\C(C)=O)=C/N(C)C LQSOVGAUOHMPLK-VURMDHGXSA-N 0.000 description 6
- ADNXCHQUIPXULO-UHFFFAOYSA-N ethyl 4-oxo-1h-pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CNC=CC1=O ADNXCHQUIPXULO-UHFFFAOYSA-N 0.000 description 6
- XCJXBWBKSPTENJ-UHFFFAOYSA-N ethyl 5-bromo-4-oxo-1H-pyridine-3-carboxylate Chemical compound CCOC(=O)c1c[nH]cc(Br)c1=O XCJXBWBKSPTENJ-UHFFFAOYSA-N 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 6
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 6
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 6
- HQYDVMOYLQJCFB-UHFFFAOYSA-N 3-fluoro-4-(1h-pyrrolo[2,3-b]pyridin-4-yloxy)aniline Chemical compound FC1=CC(N)=CC=C1OC1=CC=NC2=C1C=CN2 HQYDVMOYLQJCFB-UHFFFAOYSA-N 0.000 description 5
- HFQNSTLSFYCPAF-UHFFFAOYSA-N 3-fluoro-4-[6-methoxy-7-(2-morpholin-4-ylethoxy)quinazolin-4-yl]oxyaniline Chemical compound N1=CN=C2C=C(OCCN3CCOCC3)C(OC)=CC2=C1OC1=CC=C(N)C=C1F HFQNSTLSFYCPAF-UHFFFAOYSA-N 0.000 description 5
- ZLVVYBNEDMWIRX-UHFFFAOYSA-N 4-(6,7-dimethoxyquinazolin-4-yl)oxyaniline Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC1=CC=C(N)C=C1 ZLVVYBNEDMWIRX-UHFFFAOYSA-N 0.000 description 5
- DPMKXAHBLHVOJZ-UHFFFAOYSA-N 4-[6-methoxy-7-(2-morpholin-4-ylethoxy)quinazolin-4-yl]oxyaniline Chemical compound COC=1C=C2C(=NC=NC2=CC1OCCN1CCOCC1)OC1=CC=C(N)C=C1 DPMKXAHBLHVOJZ-UHFFFAOYSA-N 0.000 description 5
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 5
- SWDDUSNXFLHKFP-UHFFFAOYSA-N CC1(C)OC(COC(C=CC(Br)=C2)=C2OC)CO1 Chemical compound CC1(C)OC(COC(C=CC(Br)=C2)=C2OC)CO1 SWDDUSNXFLHKFP-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- SCVUXBRZMQWSHW-UHFFFAOYSA-N N-[6-[2-amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl]pyridazin-3-yl]-4-(4-fluorophenyl)-2,5-dioxo-1,8-diazatricyclo[8.4.0.03,8]tetradeca-3,6-diene-6-carboxamide Chemical compound COC1=C(C=C(C=C1)C2=CC(=C(N=C2)N)C3=NN=C(C=C3)NC(=O)C4=CN5CC6CCCCN6C(=O)C5=C(C4=O)C7=CC=C(C=C7)F)OC SCVUXBRZMQWSHW-UHFFFAOYSA-N 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 150000001335 aliphatic alkanes Chemical class 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- YWIURUUIUQXKCP-UHFFFAOYSA-N tert-butyl 4-[4-[6-amino-5-(4-amino-2-fluorophenyl)pyridin-3-yl]pyrazol-1-yl]piperidine-1-carboxylate Chemical compound NC1=C(C=C(C=N1)C=1C=NN(C=1)C1CCN(CC1)C(=O)OC(C)(C)C)C1=C(C=C(C=C1)N)F YWIURUUIUQXKCP-UHFFFAOYSA-N 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 4
- ZPHPGJGDNKUMAY-CGCSKFHYSA-N (6R)-10-(4-fluorophenyl)-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxylic acid Chemical compound C[C@@H]1COC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)O)C4=CC=C(C=C4)F ZPHPGJGDNKUMAY-CGCSKFHYSA-N 0.000 description 4
- KDKZZBSPHUQYMN-UHFFFAOYSA-N 1-cyclobutyl-5-(4-fluorophenyl)-4-oxopyridine-3-carboxylic acid Chemical compound C1(CCC1)N1C=C(C(C(=C1)C1=CC=C(C=C1)F)=O)C(=O)O KDKZZBSPHUQYMN-UHFFFAOYSA-N 0.000 description 4
- ONTBZXIDOINDGO-UHFFFAOYSA-N 1-cyclopropyl-5-(4-fluorophenyl)-4-oxopyridine-3-carboxylic acid Chemical compound OC(=O)c1cn(cc(-c2ccc(F)cc2)c1=O)C1CC1 ONTBZXIDOINDGO-UHFFFAOYSA-N 0.000 description 4
- MQHMGNRXRWNHRC-UHFFFAOYSA-N 1-tert-butyl-5-(4-fluorophenyl)-4-oxopyridine-3-carboxylic acid Chemical compound C(C)(C)(C)N1C=C(C(C(=C1)C1=CC=C(C=C1)F)=O)C(=O)O MQHMGNRXRWNHRC-UHFFFAOYSA-N 0.000 description 4
- VNHUHLJRUOXLRD-UHFFFAOYSA-N 2,3,4,8-tetrahydro-1H-pyrido[1,2-a]pyrazine-7-carboxamide Chemical compound C1C=2N(CCN1)C=C(CC2)C(=O)N VNHUHLJRUOXLRD-UHFFFAOYSA-N 0.000 description 4
- OBTNRJHVCRRFPZ-UHFFFAOYSA-N 2-(4-bromo-2-methoxyphenoxy)ethanol Chemical compound COC1=CC(Br)=CC=C1OCCO OBTNRJHVCRRFPZ-UHFFFAOYSA-N 0.000 description 4
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 4
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 4
- YLESNOXZSQMAOX-UHFFFAOYSA-N 3-(4-amino-2,5-difluorophenyl)-5-(3,4-dimethoxyphenyl)pyridin-2-amine Chemical compound COC1=C(C=C(C=C1)C2=CC(=C(N=C2)N)C3=CC(=C(C=C3F)N)F)OC YLESNOXZSQMAOX-UHFFFAOYSA-N 0.000 description 4
- VFFZXYNWVYWWNO-UHFFFAOYSA-N 3-(4-amino-2-fluorophenyl)-5-[3-methoxy-4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-amine Chemical compound COC1=C(C=CC(=C1)C2=CC(=C(N=C2)N)C3=C(C=C(C=C3)N)F)OCCN4CCOCC4 VFFZXYNWVYWWNO-UHFFFAOYSA-N 0.000 description 4
- YTNLEIURUURINW-UHFFFAOYSA-N 3-(4-amino-2-methylphenyl)-5-(3,4-dimethoxyphenyl)pyridin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C(N)C(C=2C(=CC(N)=CC=2)C)=C1 YTNLEIURUURINW-UHFFFAOYSA-N 0.000 description 4
- FLMNWVXAEGUVNY-UHFFFAOYSA-N 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N)C=C1F FLMNWVXAEGUVNY-UHFFFAOYSA-N 0.000 description 4
- GENJJHNSYQEUCX-UHFFFAOYSA-N 3-fluoro-4-[(3-iodo-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]aniline Chemical compound C1=CC(=C(C=C1N)F)OC2=C3C(=CNC3=NC=C2)I GENJJHNSYQEUCX-UHFFFAOYSA-N 0.000 description 4
- MQBWIDXXJFSQOA-UHFFFAOYSA-N 4-(2-fluoro-4-nitrophenoxy)-1h-pyrrolo[2,3-b]pyridine Chemical compound FC1=CC([N+](=O)[O-])=CC=C1OC1=CC=NC2=C1C=CN2 MQBWIDXXJFSQOA-UHFFFAOYSA-N 0.000 description 4
- WCPUFWPEMFVWPH-UHFFFAOYSA-N 4-(2-fluoro-4-nitrophenoxy)-3-iodo-1h-pyrrolo[2,3-b]pyridine Chemical compound FC1=CC([N+](=O)[O-])=CC=C1OC1=CC=NC2=C1C(I)=CN2 WCPUFWPEMFVWPH-UHFFFAOYSA-N 0.000 description 4
- VGLOGQAGFYFOPV-UHFFFAOYSA-N 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-phenylmethoxyquinazoline Chemical compound C(C1=CC=CC=C1)OC1=C(C=C2C(=NC=NC2=C1)OC1=C(C=C(C=C1)[N+](=O)[O-])F)OC VGLOGQAGFYFOPV-UHFFFAOYSA-N 0.000 description 4
- WHSIIJQOEGXWSN-UHFFFAOYSA-N 4-bromo-2-methoxyphenol Chemical compound COC1=CC(Br)=CC=C1O WHSIIJQOEGXWSN-UHFFFAOYSA-N 0.000 description 4
- WRVHQEYBCDPZEU-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinoline Chemical compound C1=CC(Cl)=C2C=C(OC)C(OC)=CC2=N1 WRVHQEYBCDPZEU-UHFFFAOYSA-N 0.000 description 4
- ZBTVNIDMGKZSGC-UHFFFAOYSA-N 4-chloro-7-methoxyquinoline-6-carboxamide Chemical compound C1=CC(Cl)=C2C=C(C(N)=O)C(OC)=CC2=N1 ZBTVNIDMGKZSGC-UHFFFAOYSA-N 0.000 description 4
- YTNQZNFJFVQJPT-UHFFFAOYSA-N 5-(4-fluorophenyl)-1-(oxan-4-ylmethyl)-4-oxopyridine-3-carboxylic acid Chemical compound FC1=CC=C(C2=CN(C=C(C2=O)C(=O)O)CC2CCOCC2)C=C1 YTNQZNFJFVQJPT-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- SWECMVUXPKZXQB-UHFFFAOYSA-N N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-8-fluoro-4-(oxan-4-ylmethyl)-1,5-dioxo-6H-benzo[f][1,7]naphthyridine-2-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC1OC)OC1=C(C=C(C=C1)NC(=O)C1=CN(C=2C(NC3=C(C2C1=O)C=CC(=C3)F)=O)CC3CCOCC3)F SWECMVUXPKZXQB-UHFFFAOYSA-N 0.000 description 4
- YHDMPMBOCPPEHS-UHFFFAOYSA-N N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-8-fluoro-4-methyl-1,5-dioxo-6H-benzo[f][1,7]naphthyridine-2-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC1OC)OC1=C(C=C(C=C1)NC(=O)C1=CN(C=2C(NC3=C(C2C1=O)C=CC(=C3)F)=O)C)F YHDMPMBOCPPEHS-UHFFFAOYSA-N 0.000 description 4
- SPWLCEOOUFPVME-UHFFFAOYSA-N N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-9-(4-fluorophenyl)-1,8-dioxo-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-7-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC1OC)OC1=C(C=C(C=C1)NC(=O)C=1C(C(=C2N(CCNC2=O)C1)C1=CC=C(C=C1)F)=O)F SPWLCEOOUFPVME-UHFFFAOYSA-N 0.000 description 4
- OYSYXSHAUIPSIE-UHFFFAOYSA-N N-[4-[2-amino-5-[3-methoxy-4-(2-morpholin-4-ylethoxy)phenyl]pyridin-3-yl]-3-fluorophenyl]-11-(4-methylphenyl)-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide Chemical compound NC1=NC=C(C=C1C1=C(C=C(C=C1)NC(=O)C=1C(C(=C2N(CC3OCCCN3C2=O)C1)C1=CC=C(C=C1)C)=O)F)C1=CC(=C(C=C1)OCCN1CCOCC1)OC OYSYXSHAUIPSIE-UHFFFAOYSA-N 0.000 description 4
- FNJFXPQAVMEMIC-UHFFFAOYSA-N O1C=CN2C1=CN1C(=C2)C=CC(=C1)C(=O)N Chemical compound O1C=CN2C1=CN1C(=C2)C=CC(=C1)C(=O)N FNJFXPQAVMEMIC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000006069 Suzuki reaction reaction Methods 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 4
- 229960001292 cabozantinib Drugs 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000006482 condensation reaction Methods 0.000 description 4
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 4
- DRIILOQPYIFAGM-UHFFFAOYSA-N diethyl 1-(oxan-4-ylmethyl)-4-oxopyridine-2,5-dicarboxylate Chemical compound CCOC(=O)C1=CC(=O)C(=CN1CC2CCOCC2)C(=O)OCC DRIILOQPYIFAGM-UHFFFAOYSA-N 0.000 description 4
- KBAZKYJZBAUSCS-UHFFFAOYSA-N diethyl 3-(4-fluorophenyl)-1-methyl-4-oxopyridine-2,5-dicarboxylate Chemical compound CCOC(=O)C1=CN(C(=C(C1=O)C2=CC=C(C=C2)F)C(=O)OCC)C KBAZKYJZBAUSCS-UHFFFAOYSA-N 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- DDDSGYZATMCUDW-UHFFFAOYSA-N methyl 4-chloro-7-methoxyquinoline-6-carboxylate Chemical compound C1=CN=C2C=C(OC)C(C(=O)OC)=CC2=C1Cl DDDSGYZATMCUDW-UHFFFAOYSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- IRSSIQNSBCQILH-UHFFFAOYSA-N tert-butyl 3-(aminomethyl)morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOCC1CN IRSSIQNSBCQILH-UHFFFAOYSA-N 0.000 description 4
- IQZCSWSXDHWKEV-UHFFFAOYSA-N tert-butyl 4-(2-fluoro-4-nitrophenoxy)-3-iodopyrrolo[2,3-b]pyridine-1-carboxylate Chemical compound C1=CN=C2N(C(=O)OC(C)(C)C)C=C(I)C2=C1OC1=CC=C([N+]([O-])=O)C=C1F IQZCSWSXDHWKEV-UHFFFAOYSA-N 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- ZPHPGJGDNKUMAY-LLTODGECSA-N (6S)-10-(4-fluorophenyl)-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxylic acid Chemical compound C[C@H]1COC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)O)C4=CC=C(C=C4)F ZPHPGJGDNKUMAY-LLTODGECSA-N 0.000 description 3
- FVYLSRJGBURREK-UHFFFAOYSA-N 1-(3-aminopropyl)-6-ethoxycarbonyl-4-oxopyridine-3-carboxylic acid hydrochloride Chemical compound Cl.C(C)OC(=O)C=1N(C=C(C(C1)=O)C(=O)O)CCCN FVYLSRJGBURREK-UHFFFAOYSA-N 0.000 description 3
- JFIVCUYNSCVUMG-UHFFFAOYSA-N 11-(4-fluorophenyl)-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxylic acid Chemical compound C1CN2C(CN3C=C(C(=O)C(=C3C2=O)C4=CC=C(C=C4)F)C(=O)O)OC1 JFIVCUYNSCVUMG-UHFFFAOYSA-N 0.000 description 3
- POXWDTQUDZUOGP-UHFFFAOYSA-N 1h-1,4-diazepine Chemical compound N1C=CC=NC=C1 POXWDTQUDZUOGP-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- BLAHKHDCYYFYCE-UHFFFAOYSA-N 3-(4-amino-2-fluorophenyl)-5-bromopyridin-2-amine Chemical compound FC1=CC(N)=CC=C1C1=CC(Br)=CN=C1N BLAHKHDCYYFYCE-UHFFFAOYSA-N 0.000 description 3
- LFMIPDKMNCWUCX-UHFFFAOYSA-N 3-(4-bromo-2-methoxyphenoxy)propane-1,2-diol Chemical compound COC1=C(C=CC(=C1)Br)OCC(CO)O LFMIPDKMNCWUCX-UHFFFAOYSA-N 0.000 description 3
- OYZOHRSCEASBER-UHFFFAOYSA-N 3-bromo-5-iodopyridin-2-amine Chemical compound NC1=NC=C(I)C=C1Br OYZOHRSCEASBER-UHFFFAOYSA-N 0.000 description 3
- XNXWWERVRFAOPG-UHFFFAOYSA-N 4-(1h-pyrrolo[2,3-b]pyridin-4-yloxy)aniline Chemical compound C1=CC(N)=CC=C1OC1=CC=NC2=C1C=CN2 XNXWWERVRFAOPG-UHFFFAOYSA-N 0.000 description 3
- ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 3
- MVIKFGGFPRSQFD-UHFFFAOYSA-N 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-(2-methoxyethoxy)quinazoline Chemical compound FC1=C(OC2=NC=NC3=CC(=C(C=C23)OC)OCCOC)C=CC(=C1)[N+](=O)[O-] MVIKFGGFPRSQFD-UHFFFAOYSA-N 0.000 description 3
- KASVUTUUUAJHNQ-UHFFFAOYSA-N 4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline-6-carboxamide Chemical compound COC1=C(C=C2C(OC3=CC=C(C=C3F)[N+]([O-])=O)=CC=NC2=C1)C(N)=O KASVUTUUUAJHNQ-UHFFFAOYSA-N 0.000 description 3
- HOLZLIMOCQUAGJ-UHFFFAOYSA-N 4-(2-fluoro-4-nitrophenyl)-6-methylquinazolin-7-ol Chemical compound FC1=C(C=CC(=C1)[N+](=O)[O-])C1=NC=NC2=CC(=C(C=C12)C)O HOLZLIMOCQUAGJ-UHFFFAOYSA-N 0.000 description 3
- FGMUTXIVAWGGAL-UHFFFAOYSA-N 4-(4-nitrophenoxy)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=NC2=C1C=CN2 FGMUTXIVAWGGAL-UHFFFAOYSA-N 0.000 description 3
- MVKHWXHKSLSASW-UHFFFAOYSA-N 4-(6,7-dimethoxyquinazolin-4-yl)oxy-3-fluoroaniline Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC1=CC=C(N)C=C1F MVKHWXHKSLSASW-UHFFFAOYSA-N 0.000 description 3
- WGWSXASITIMNNK-UHFFFAOYSA-N 4-(6-chloropyridazin-3-yl)oxy-6,7-dimethoxyquinoline Chemical compound COC1=C(OC)C=C2C(OC3=NN=C(Cl)C=C3)=CC=NC2=C1 WGWSXASITIMNNK-UHFFFAOYSA-N 0.000 description 3
- KVXXEKIGMOEPSA-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonyl]morpholine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCOCC1C(O)=O KVXXEKIGMOEPSA-UHFFFAOYSA-N 0.000 description 3
- VYKNKHXCGOEONI-UHFFFAOYSA-N 4-[2-(4-bromo-2-methoxyphenoxy)ethyl]morpholine Chemical compound COC1=CC(Br)=CC=C1OCCN1CCOCC1 VYKNKHXCGOEONI-UHFFFAOYSA-N 0.000 description 3
- PSEZWVYGHDQMJO-UHFFFAOYSA-N 4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]oxyaniline Chemical compound COC=1C=C2C(=NC=NC2=CC=1OCCOC)OC1=CC=C(N)C=C1 PSEZWVYGHDQMJO-UHFFFAOYSA-N 0.000 description 3
- DLNLQBDTLPXWJZ-UHFFFAOYSA-N 4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-2,13-diene-13-carboxamide Chemical compound O1C=2N(CCC1)CC1N(C=2)C=C(CC1)C(=O)N DLNLQBDTLPXWJZ-UHFFFAOYSA-N 0.000 description 3
- GUNRQFXLKYTKGC-UHFFFAOYSA-N 4H-pyrido[1,2-a]pyrazine-8-carboxylic acid Chemical compound C1=C2N(CC=N1)C=CC(=C2)C(=O)O GUNRQFXLKYTKGC-UHFFFAOYSA-N 0.000 description 3
- QSWQLKGNAPVPEX-UHFFFAOYSA-N 5,6-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide Chemical compound O=C1C(OC2N1CC=1N(C2)C=C(CC=1)C(=O)N)=O QSWQLKGNAPVPEX-UHFFFAOYSA-N 0.000 description 3
- IZONJUZIAYLCNY-UHFFFAOYSA-N 5-(4-fluorophenyl)-1-methyl-4-oxopyridine-3-carboxamide Chemical compound CN1C=C(C(N)=O)C(=O)C(C=2C=CC(F)=CC=2)=C1 IZONJUZIAYLCNY-UHFFFAOYSA-N 0.000 description 3
- HBQIVHSNASMHFK-UHFFFAOYSA-N 9-(4-fluorophenyl)-1,8-dioxo-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-7-carboxylic acid Chemical compound C1CN2C=C(C(=O)C(=C2C(=O)N1)C3=CC=C(C=C3)F)C(=O)O HBQIVHSNASMHFK-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 101150022345 GAS6 gene Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000009435 amidation Effects 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- ZUSACPOXJBLPDC-UHFFFAOYSA-N diethyl 1-methyl-4-oxopyridine-2,5-dicarboxylate Chemical compound CCOC(=O)C1=CC(=O)C(=CN1C)C(=O)OCC ZUSACPOXJBLPDC-UHFFFAOYSA-N 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- YPMAKVVNKLKXJT-UHFFFAOYSA-N ethyl 5-[[6-[2-amino-5-(1-piperidin-4-ylpyrazol-4-yl)-1H-pyridazin-3-yl]pyridin-3-yl]carbamoyl]-3-(4-fluorophenyl)-1-methyl-4-oxopyridine-2-carboxylate Chemical compound C(C)OC(=O)C=1N(C=C(C(C1C1=CC=C(C=C1)F)=O)C(NC=1C=NC(=CC1)C=1N(NC=C(C1)C=1C=NN(C1)C1CCNCC1)N)=O)C YPMAKVVNKLKXJT-UHFFFAOYSA-N 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- TYKSVPGCVLNVIO-UHFFFAOYSA-N methyl 7-methoxy-4-oxo-1h-quinoline-6-carboxylate Chemical compound N1C=CC(=O)C2=C1C=C(OC)C(C(=O)OC)=C2 TYKSVPGCVLNVIO-UHFFFAOYSA-N 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000002092 orthoester group Chemical group 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- AMDFBQXRVZTTKM-UHFFFAOYSA-N tert-butyl 3-carbamoylmorpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOCC1C(N)=O AMDFBQXRVZTTKM-UHFFFAOYSA-N 0.000 description 3
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Natural products NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- RCVDPBFUMYUKPB-UHFFFAOYSA-N (3,4-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1OC RCVDPBFUMYUKPB-UHFFFAOYSA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- LCSOANRMIBQCCG-UHFFFAOYSA-N 10-(4-fluorophenyl)-8,11-dioxo-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxylic acid Chemical compound FC1=CC=C(C=C1)C=1C(C(=CN2C1C(N1C(C2)CCC1)=O)C(=O)O)=O LCSOANRMIBQCCG-UHFFFAOYSA-N 0.000 description 2
- LXTUZXPPZPGCJB-UHFFFAOYSA-N 10-(4-methylphenyl)-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxylic acid Chemical compound CC1=CC=C(C=C1)C2=C3C(=O)N4CCOC4CN3C=C(C2=O)C(=O)O LXTUZXPPZPGCJB-UHFFFAOYSA-N 0.000 description 2
- XSQDDQXYJKRDOP-UHFFFAOYSA-N 11-(4-fluorophenyl)-9,12-dioxo-5-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxylic acid Chemical compound FC1=CC=C(C=C1)C=1C(C(=CN2CC3COCCN3C(C21)=O)C(=O)O)=O XSQDDQXYJKRDOP-UHFFFAOYSA-N 0.000 description 2
- FYOZOJUWLMVYQX-UHFFFAOYSA-N 11-(4-methylphenyl)-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxylic acid Chemical compound O=C1C=2N(CC3OCCCN31)C=C(C(C2C2=CC=C(C=C2)C)=O)C(=O)O FYOZOJUWLMVYQX-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- SOHBHFWRCLJGDV-UHFFFAOYSA-N 2,5-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC(F)=C(N)C=C1F SOHBHFWRCLJGDV-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- PFNXEYVLRGZYLD-UHFFFAOYSA-N 2-[(4-bromo-2-methoxyphenoxy)methyl]-1,4-dioxane Chemical compound BrC1=CC(=C(OCC2OCCOC2)C=C1)OC PFNXEYVLRGZYLD-UHFFFAOYSA-N 0.000 description 2
- LNNBUYGWXRXGDB-UHFFFAOYSA-N 2-[tert-butyl(diphenyl)silyl]oxypropane-1,3-diamine Chemical compound [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)OC(CN)CN LNNBUYGWXRXGDB-UHFFFAOYSA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 2
- FZALZSCZGWTUDA-UHFFFAOYSA-N 3-(6-bromopyridazin-3-yl)-5-(4-fluorophenyl)-1-(oxan-4-ylmethyl)-4-oxo-2H-pyridine-3,6-dicarboxamide Chemical compound BrC1=CC=C(N=N1)C1(C(C(=C(N(C1)CC1CCOCC1)C(=O)N)C1=CC=C(C=C1)F)=O)C(=O)N FZALZSCZGWTUDA-UHFFFAOYSA-N 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- ZANPJXNYBVVNSD-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N)C=C1 ZANPJXNYBVVNSD-UHFFFAOYSA-N 0.000 description 2
- AWAOTKYAHSYQNA-UHFFFAOYSA-N 4-(4-amino-2-fluorophenoxy)pyridin-2-amine Chemical compound FC1=CC(N)=CC=C1OC1=CC=NC(N)=C1 AWAOTKYAHSYQNA-UHFFFAOYSA-N 0.000 description 2
- HNTZVGMWXCFCTA-UHFFFAOYSA-N 4-chloro-1h-pyrrolo[2,3-b]pyridine Chemical compound ClC1=CC=NC2=C1C=CN2 HNTZVGMWXCFCTA-UHFFFAOYSA-N 0.000 description 2
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- ZUGCTOCXXOBIER-UHFFFAOYSA-N 5-[[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]carbamoyl]-3-(4-fluorophenyl)-1-methyl-4-oxopyridine-2-carboxylic acid Chemical compound COC=1C=C2C(=CC=NC2=CC1OC)OC1=C(C=C(C=C1)NC(=O)C=1C(C(=C(N(C1)C)C(=O)O)C1=CC=C(C=C1)F)=O)F ZUGCTOCXXOBIER-UHFFFAOYSA-N 0.000 description 2
- XPERZSKJGNUSHI-UHFFFAOYSA-N 5-bromo-3-iodopyridin-2-amine Chemical compound NC1=NC=C(Br)C=C1I XPERZSKJGNUSHI-UHFFFAOYSA-N 0.000 description 2
- FXTDHDQFLZNYKW-UHFFFAOYSA-N 6-bromopyridazin-3-amine Chemical compound NC1=CC=C(Br)N=N1 FXTDHDQFLZNYKW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 2
- TWLKOSSTJBHFNU-UHFFFAOYSA-N N-[(2,4-dimethoxyphenyl)methyl]-6-(6,7-dimethylquinolin-4-yl)oxypyridazin-3-amine Chemical compound COC1=C(CNC=2N=NC(=CC2)OC2=CC=NC3=CC(=C(C=C23)C)C)C=CC(=C1)OC TWLKOSSTJBHFNU-UHFFFAOYSA-N 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108091077436 Tam family Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- QYXKVNDIRTVBFT-UHFFFAOYSA-N diethyl 3-bromo-1-(2,2-dimethoxyethyl)-4-oxopyridine-2,5-dicarboxylate Chemical compound CCOC(=O)C1=CN(CC(OC)OC)C(C(=O)OCC)=C(Br)C1=O QYXKVNDIRTVBFT-UHFFFAOYSA-N 0.000 description 2
- TUDZUAREIDNWSU-UHFFFAOYSA-N diethyl 3-bromo-1-(oxan-4-ylmethyl)-4-oxopyridine-2,5-dicarboxylate Chemical compound C(C)OC(=O)C=1N(C=C(C(C1Br)=O)C(=O)OCC)CC1CCOCC1 TUDZUAREIDNWSU-UHFFFAOYSA-N 0.000 description 2
- LDWLWKXYFPPLCA-UHFFFAOYSA-N diethyl 3-bromo-4-oxo-1-(piperidin-2-ylmethyl)pyridine-2,5-dicarboxylate hydrochloride Chemical compound Cl.C(C)OC(=O)C=1N(C=C(C(C1Br)=O)C(=O)OCC)CC1NCCCC1 LDWLWKXYFPPLCA-UHFFFAOYSA-N 0.000 description 2
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 2
- AFWWHZBUQWEDLS-UHFFFAOYSA-N diethyl pyridine-2,5-dicarboxylate Chemical compound CCOC(=O)C1=CC=C(C(=O)OCC)N=C1 AFWWHZBUQWEDLS-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- SZYQPTAROQANMV-UHFFFAOYSA-N ethyl pyrazine-2-carboxylate Chemical compound CCOC(=O)C1=CN=CC=N1 SZYQPTAROQANMV-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- PTVRCUVHYMGECC-UHFFFAOYSA-N tert-butyl 2-(aminomethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1CN PTVRCUVHYMGECC-UHFFFAOYSA-N 0.000 description 2
- MYOWELLYEZMECA-UHFFFAOYSA-N tert-butyl 4-(2-chloroethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CCCl)CC1 MYOWELLYEZMECA-UHFFFAOYSA-N 0.000 description 2
- QGZVYZUKTVLWDA-UHFFFAOYSA-N tert-butyl 4-[4-(6-amino-5-bromopyridin-3-yl)pyrazol-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1N=CC(C=2C=C(Br)C(N)=NC=2)=C1 QGZVYZUKTVLWDA-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
- PYEDYJJGEREHLN-UHFFFAOYSA-N (2-amino-4-fluorophenyl)boronic acid Chemical compound NC1=CC(F)=CC=C1B(O)O PYEDYJJGEREHLN-UHFFFAOYSA-N 0.000 description 1
- DIRRKLFMHQUJCM-UHFFFAOYSA-N (2-aminophenyl)boronic acid Chemical compound NC1=CC=CC=C1B(O)O DIRRKLFMHQUJCM-UHFFFAOYSA-N 0.000 description 1
- BKMMTJMQCTUHRP-GSVOUGTGSA-N (2r)-2-aminopropan-1-ol Chemical compound C[C@@H](N)CO BKMMTJMQCTUHRP-GSVOUGTGSA-N 0.000 description 1
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical compound CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 description 1
- AGMZSYQMSHMXLT-SCSAIBSYSA-N (3r)-3-aminobutan-1-ol Chemical compound C[C@@H](N)CCO AGMZSYQMSHMXLT-SCSAIBSYSA-N 0.000 description 1
- NRIYPIBRPGAWDD-UHFFFAOYSA-N (5-methylthiophen-2-yl)boronic acid Chemical compound CC1=CC=C(B(O)O)S1 NRIYPIBRPGAWDD-UHFFFAOYSA-N 0.000 description 1
- MZUSCPDSQJSBSY-UHFFFAOYSA-N (6-methylpyridin-3-yl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=N1 MZUSCPDSQJSBSY-UHFFFAOYSA-N 0.000 description 1
- PBKWODBUDOYSKA-IAPIXIRKSA-N (7R)-11-(4-fluorophenyl)-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxylic acid Chemical compound FC1=CC=C(C=C1)C=1C(C(=CN2CC3OCC[C@H](N3C(C21)=O)C)C(=O)O)=O PBKWODBUDOYSKA-IAPIXIRKSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BKMMTJMQCTUHRP-VKHMYHEASA-N (S)-2-aminopropan-1-ol Chemical compound C[C@H](N)CO BKMMTJMQCTUHRP-VKHMYHEASA-N 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- KTCNGKASVZVXHT-UHFFFAOYSA-N 1,2-dihydropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CNC1 KTCNGKASVZVXHT-UHFFFAOYSA-N 0.000 description 1
- UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 description 1
- INYAEKPOADCZOU-UHFFFAOYSA-N 1-(2,2-dimethoxyethyl)-4-oxopyridine-2,5-dicarboxylic acid Chemical compound C(OC)(CN1C(=CC(=O)C(=C1)C(=O)O)C(=O)O)OC INYAEKPOADCZOU-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- GGDXELDBKMSJSV-UHFFFAOYSA-N 1-methyl-4-oxopyridine-2-carboxylic acid Chemical compound CN1C=CC(=O)C=C1C(O)=O GGDXELDBKMSJSV-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 description 1
- UUDALWDRIFYZPM-UHFFFAOYSA-N 1h-pyridine-2,4-dione Chemical compound O=C1CC(=O)C=CN1 UUDALWDRIFYZPM-UHFFFAOYSA-N 0.000 description 1
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LYIIBVSRGJSHAV-UHFFFAOYSA-N 2-aminoacetaldehyde Chemical compound NCC=O LYIIBVSRGJSHAV-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- GUSWJGOYDXFJSI-UHFFFAOYSA-N 3,6-dichloropyridazine Chemical compound ClC1=CC=C(Cl)N=N1 GUSWJGOYDXFJSI-UHFFFAOYSA-N 0.000 description 1
- AZUQCSTULXARIP-UHFFFAOYSA-N 3-(4-amino-2-fluorophenyl)-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine tert-butyl formate Chemical compound C(=O)OC(C)(C)C.NC1=C(C=C(C=N1)C=1C=NN(C1)C1CCNCC1)C1=C(C=C(C=C1)N)F AZUQCSTULXARIP-UHFFFAOYSA-N 0.000 description 1
- PYIVNGBQMPHEDY-UHFFFAOYSA-N 3-(4-amino-2-fluorophenyl)-5-[4-(1,4-dioxan-2-ylmethoxy)-3-methoxyphenyl]pyridin-2-amine Chemical compound COC1=C(OCC2COCCO2)C=CC(=C1)C1=CN=C(N)C(=C1)C1=CC=C(N)C=C1F PYIVNGBQMPHEDY-UHFFFAOYSA-N 0.000 description 1
- IFCSWGQBKVTSFE-UHFFFAOYSA-N 3-(4-aminophenyl)-5-(3,4-dimethoxyphenyl)pyridin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C(N)C(C=2C=CC(N)=CC=2)=C1 IFCSWGQBKVTSFE-UHFFFAOYSA-N 0.000 description 1
- DSCZXVLLSQYRJC-UHFFFAOYSA-N 3-(4-aminophenyl)-5-[1-(oxan-4-yl)pyrazol-4-yl]pyridin-2-amine Chemical compound NC1=CC=C(C=C1)C=1C(=NC=C(C1)C=1C=NN(C1)C1CCOCC1)N DSCZXVLLSQYRJC-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MTEHIBOSVAKGNH-UHFFFAOYSA-N 3-bromo-5-(3,4-dimethoxyphenyl)pyridine Chemical compound BrC=1C=NC=C(C=1)C1=CC(=C(C=C1)OC)OC MTEHIBOSVAKGNH-UHFFFAOYSA-N 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- LLLHRNQLGUOJHP-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinazoline Chemical compound C1=NC(Cl)=C2C=C(OC)C(OC)=CC2=N1 LLLHRNQLGUOJHP-UHFFFAOYSA-N 0.000 description 1
- LBGIYCBNJBHZSZ-UHFFFAOYSA-N 4-chloro-6-methoxy-7-phenylmethoxyquinazoline Chemical compound COC1=CC2=C(Cl)N=CN=C2C=C1OCC1=CC=CC=C1 LBGIYCBNJBHZSZ-UHFFFAOYSA-N 0.000 description 1
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- DVLSQHLXPRYYRC-UHFFFAOYSA-N 5-(methoxymethylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound COC=C1C(=O)OC(C)(C)OC1=O DVLSQHLXPRYYRC-UHFFFAOYSA-N 0.000 description 1
- VJUROJBWDHBLOX-UHFFFAOYSA-N 5-[(3-methoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound COC1=CC=CC(NC=C2C(OC(C)(C)OC2=O)=O)=C1 VJUROJBWDHBLOX-UHFFFAOYSA-N 0.000 description 1
- BTIPVJQBXSFISK-UHFFFAOYSA-N 5-bromo-1H-pyridazin-2-amine Chemical compound NN1NC=C(Br)C=C1 BTIPVJQBXSFISK-UHFFFAOYSA-N 0.000 description 1
- WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 1
- IVILGUFRMDBUEQ-UHFFFAOYSA-N 5-iodopyridin-2-amine Chemical compound NC1=CC=C(I)C=N1 IVILGUFRMDBUEQ-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- QOGPNCUTXVZQSL-UHFFFAOYSA-N 6,7-dimethoxy-1h-quinolin-4-one Chemical compound C1=CC(O)=C2C=C(OC)C(OC)=CC2=N1 QOGPNCUTXVZQSL-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 101150018445 Axl gene Proteins 0.000 description 1
- 238000011728 BALB/c nude (JAX™ mouse strain) Methods 0.000 description 1
- UOEQJPJYEMGNAP-UHFFFAOYSA-N BC1=C(C(OCC)=O)N(CC2CCOCC2)C=C(C(O)=O)C1=O Chemical compound BC1=C(C(OCC)=O)N(CC2CCOCC2)C=C(C(O)=O)C1=O UOEQJPJYEMGNAP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 240000008564 Boehmeria nivea Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BJPRIPPRGLOJOX-RELWKKBWSA-N C/C(/c1cc(-c(c(F)c2)ccc2NC(C2=CN(CCCNC3=O)C3=C(c3ccc(C)cc3)C2=O)=O)c(N)nc1)=C\NC1CCOCC1 Chemical compound C/C(/c1cc(-c(c(F)c2)ccc2NC(C2=CN(CCCNC3=O)C3=C(c3ccc(C)cc3)C2=O)=O)c(N)nc1)=C\NC1CCOCC1 BJPRIPPRGLOJOX-RELWKKBWSA-N 0.000 description 1
- GXROBOQZDDISTR-UHFFFAOYSA-N C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1.C1(=CC=CC=C1)PC1=CC=CC=C1 Chemical compound C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1.C1(=CC=CC=C1)PC1=CC=CC=C1 GXROBOQZDDISTR-UHFFFAOYSA-N 0.000 description 1
- HHTIUYLCZXLWPB-UHFFFAOYSA-N C=1OC=CN2C1C(=NC=C2)C(=O)O Chemical compound C=1OC=CN2C1C(=NC=C2)C(=O)O HHTIUYLCZXLWPB-UHFFFAOYSA-N 0.000 description 1
- GVSSKTZAUSTTKA-UHFFFAOYSA-N C=CN(C(CCNC1)C1CNC1=O)C1=C Chemical compound C=CN(C(CCNC1)C1CNC1=O)C1=C GVSSKTZAUSTTKA-UHFFFAOYSA-N 0.000 description 1
- SEAUCYXBVVRLML-UHFFFAOYSA-N C=CN(C(COC1)C1NC1=O)C1=C Chemical compound C=CN(C(COC1)C1NC1=O)C1=C SEAUCYXBVVRLML-UHFFFAOYSA-N 0.000 description 1
- OOKHOHKZQYZQAL-UHFFFAOYSA-N CC(C(NC1C2COCC1)=O)N2C=C Chemical compound CC(C(NC1C2COCC1)=O)N2C=C OOKHOHKZQYZQAL-UHFFFAOYSA-N 0.000 description 1
- PWVBAGDILHNRFE-UHFFFAOYSA-N CC(C(NCC1C2CCOC1)=O)N2C=C Chemical compound CC(C(NCC1C2CCOC1)=O)N2C=C PWVBAGDILHNRFE-UHFFFAOYSA-N 0.000 description 1
- NFOYIAOKYJYVPZ-UHFFFAOYSA-N CC(C(NCC1OCCC11)=O)N1C=C Chemical compound CC(C(NCC1OCCC11)=O)N1C=C NFOYIAOKYJYVPZ-UHFFFAOYSA-N 0.000 description 1
- VKZZTURMFKOWFR-UHFFFAOYSA-N CC(C(NCCC1)=O)N1C=C Chemical compound CC(C(NCCC1)=O)N1C=C VKZZTURMFKOWFR-UHFFFAOYSA-N 0.000 description 1
- QRMRGWHZEPDTRV-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1[n]1ncc(C2=CCCN=C2)c1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1[n]1ncc(C2=CCCN=C2)c1)=O QRMRGWHZEPDTRV-UHFFFAOYSA-N 0.000 description 1
- ZABGQRMKTCBTIT-UHFFFAOYSA-N CC1N(C)CCNC1=O Chemical compound CC1N(C)CCNC1=O ZABGQRMKTCBTIT-UHFFFAOYSA-N 0.000 description 1
- HCOAGFDTQLYOOS-UHFFFAOYSA-N CCOC(C(N(CC1CCOCC1)C=C(C(Nc(cc1)cc(F)c1Oc1c(cc(c(OC)c2)OC)c2ncc1)=O)C1=O)=C1Br)=O Chemical compound CCOC(C(N(CC1CCOCC1)C=C(C(Nc(cc1)cc(F)c1Oc1c(cc(c(OC)c2)OC)c2ncc1)=O)C1=O)=C1Br)=O HCOAGFDTQLYOOS-UHFFFAOYSA-N 0.000 description 1
- OTYYBJNSLLBAGE-UHFFFAOYSA-N CN1C(CCC1)=O.[N] Chemical compound CN1C(CCC1)=O.[N] OTYYBJNSLLBAGE-UHFFFAOYSA-N 0.000 description 1
- QOGCHNWWXQLEKU-UHFFFAOYSA-N COc(c(O)cc1ncn2)cc1c2Oc(ccc([N+]([O-])=O)c1)c1F Chemical compound COc(c(O)cc1ncn2)cc1c2Oc(ccc([N+]([O-])=O)c1)c1F QOGCHNWWXQLEKU-UHFFFAOYSA-N 0.000 description 1
- WBYULBQCZBRSHW-UHFFFAOYSA-N COc(c(OC)cc1ncc2)cc1c2Oc(ccc(NC(C1=CN(CC2OCCN2C2=O)C2=C(c(cc2)ccc2F)C1=O)=O)c1)c1F Chemical compound COc(c(OC)cc1ncc2)cc1c2Oc(ccc(NC(C1=CN(CC2OCCN2C2=O)C2=C(c(cc2)ccc2F)C1=O)=O)c1)c1F WBYULBQCZBRSHW-UHFFFAOYSA-N 0.000 description 1
- XQIAJLNINXRLGD-UHFFFAOYSA-N COc(ccc(-c(cc1-c(c(F)c2)ccc2NC(C2=CN(CCCNC3=O)C3=C(c(cc3)ccc3F)C2=O)=O)cnc1N)c1)c1OC Chemical compound COc(ccc(-c(cc1-c(c(F)c2)ccc2NC(C2=CN(CCCNC3=O)C3=C(c(cc3)ccc3F)C2=O)=O)cnc1N)c1)c1OC XQIAJLNINXRLGD-UHFFFAOYSA-N 0.000 description 1
- SSJUTVPGYQQCHN-UHFFFAOYSA-N COc1cc2c(C3CCC3)ncnc2cc1OCc1ccccc1 Chemical compound COc1cc2c(C3CCC3)ncnc2cc1OCc1ccccc1 SSJUTVPGYQQCHN-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101800001318 Capsid protein VP4 Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- RHNMFIDCZCFUJK-UHFFFAOYSA-N N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-11-(4-fluorophenyl)-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC1OC)OC1=C(C=C(C=C1)NC(=O)C=1C(C(=C2N(CC3OCCCN3C2=O)C1)C1=CC=C(C=C1)F)=O)F RHNMFIDCZCFUJK-UHFFFAOYSA-N 0.000 description 1
- XIOAJPRUWQACHU-UHFFFAOYSA-N N-[4-(6-carbamoyl-7-methoxyquinolin-4-yl)oxy-3-fluorophenyl]-10-(4-fluorophenyl)-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide Chemical compound C(N)(=O)C=1C=C2C(=CC=NC2=CC1OC)OC1=C(C=C(C=C1)NC(=O)C=1C(C(=C2N(CC3N(C2=O)CCO3)C1)C1=CC=C(C=C1)F)=O)F XIOAJPRUWQACHU-UHFFFAOYSA-N 0.000 description 1
- YKJRJEJNKJLOHO-UHFFFAOYSA-N N-[4-[2-amino-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-3-yl]-3-fluorophenyl]-9-(4-fluorophenyl)-1,8-dioxo-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-7-carboxamide Chemical compound NC1=NC=C(C=C1C1=C(C=C(C=C1)NC(=O)C=1C(C(=C2N(CCNC2=O)C1)C1=CC=C(C=C1)F)=O)F)C=1C=NN(C1)C1CCNCC1 YKJRJEJNKJLOHO-UHFFFAOYSA-N 0.000 description 1
- VWRKGBIZXJHFRO-UHFFFAOYSA-N N-[4-[2-amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl]-3-fluorophenyl]-10-(4-fluorophenyl)-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide Chemical compound NC1=NC=C(C=C1C1=C(C=C(C=C1)NC(=O)C=1C(C(=C2N(CC3N(C2=O)CCO3)C1)C1=CC=C(C=C1)F)=O)F)C1=CC(=C(C=C1)OC)OC VWRKGBIZXJHFRO-UHFFFAOYSA-N 0.000 description 1
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 description 1
- SCINGTQEPRJPPF-UHFFFAOYSA-N NC1=C(C=C(C=N1)C=1C=NN(C1)C1CCN(CC1)C(=O)O)C1=C(C=C(C=C1)N)F Chemical compound NC1=C(C=C(C=N1)C=1C=NN(C1)C1CCN(CC1)C(=O)O)C1=C(C=C(C=C1)N)F SCINGTQEPRJPPF-UHFFFAOYSA-N 0.000 description 1
- OMEBDWVASCRXPK-UHFFFAOYSA-N Nc(c(-c(cc(c(NC(C1=CN(CCCNC2=O)C2=C(c(cc2)ccc2F)C1=O)=O)c1)F)c1F)c1)ncc1-c1c[n](C2CCNCC2)nc1 Chemical compound Nc(c(-c(cc(c(NC(C1=CN(CCCNC2=O)C2=C(c(cc2)ccc2F)C1=O)=O)c1)F)c1F)c1)ncc1-c1c[n](C2CCNCC2)nc1 OMEBDWVASCRXPK-UHFFFAOYSA-N 0.000 description 1
- UMBBYXDJMQFWFA-UHFFFAOYSA-N Nc(ncc(-c1c[n](C2CCNCC2)cc1)c1)c1-c(c(F)c1)ccc1NC(C1=CN(CC2CCOCC2)C(C(Nc2c3ccc(F)c2)=O)=C3C1=O)=O Chemical compound Nc(ncc(-c1c[n](C2CCNCC2)cc1)c1)c1-c(c(F)c1)ccc1NC(C1=CN(CC2CCOCC2)C(C(Nc2c3ccc(F)c2)=O)=C3C1=O)=O UMBBYXDJMQFWFA-UHFFFAOYSA-N 0.000 description 1
- DFHLRIOUJLGQIZ-UHFFFAOYSA-N O1C=2N(CCC1)CC1N(C2)C=C(CC1)C(=O)O Chemical compound O1C=2N(CCC1)CC1N(C2)C=C(CC1)C(=O)O DFHLRIOUJLGQIZ-UHFFFAOYSA-N 0.000 description 1
- VXTGGRNZAYDSEH-UHFFFAOYSA-N O=C(C1=CN(CC2CCOCC2)C(C(Nc2cc(F)ccc22)=O)=C2C1=O)NC1N=CC(c2c[n](C3CCNCC3)nc2)=CC1 Chemical compound O=C(C1=CN(CC2CCOCC2)C(C(Nc2cc(F)ccc22)=O)=C2C1=O)NC1N=CC(c2c[n](C3CCNCC3)nc2)=CC1 VXTGGRNZAYDSEH-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000012515 Protein kinase domains Human genes 0.000 description 1
- 108050002122 Protein kinase domains Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 108010023337 axl receptor tyrosine kinase Proteins 0.000 description 1
- JXHSZQZCKLNUGB-UHFFFAOYSA-N aziridine;hydrochloride Chemical compound Cl.C1CN1 JXHSZQZCKLNUGB-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- LBIIAJYHRQDSPB-UHFFFAOYSA-N boric acid;fluorobenzene Chemical compound OB(O)O.FC1=CC=CC=C1 LBIIAJYHRQDSPB-UHFFFAOYSA-N 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- VBXDEEVJTYBRJJ-UHFFFAOYSA-N diboronic acid Chemical compound OBOBO VBXDEEVJTYBRJJ-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- AUROYTDVINZGRW-UHFFFAOYSA-N diethyl 1,4-dihydropyridine-2,5-dicarboxylate Chemical compound C(C)OC(=O)C=1NC=C(CC=1)C(=O)OCC AUROYTDVINZGRW-UHFFFAOYSA-N 0.000 description 1
- UURPNOXFSMLWLF-UHFFFAOYSA-N diethyl 1-(2,2-dimethoxyethyl)-4-oxopyridine-2,5-dicarboxylate Chemical compound CCOC(=O)C1=CC(=O)C(C(=O)OCC)=CN1CC(OC)OC UURPNOXFSMLWLF-UHFFFAOYSA-N 0.000 description 1
- LCKRLDOIRFCGKF-UHFFFAOYSA-N diethyl 1-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-2-yl]methyl]-4-oxopyridine-2,5-dicarboxylate Chemical compound C(C)OC(=O)C=1N(C=C(C(C1)=O)C(=O)OCC)CC1N(CCCC1)C(=O)OC(C)(C)C LCKRLDOIRFCGKF-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- ABSPZHOHYYFCJR-UHFFFAOYSA-N ethyl 4-bromo-2,5-dioxo-1,8-diazatricyclo[8.4.0.03,8]tetradeca-3,6-diene-6-carboxylate Chemical compound C(C)OC(=O)C=1C(C(=C2N(CC3N(C2=O)CCCC3)C1)Br)=O ABSPZHOHYYFCJR-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229950008692 foretinib Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 108010004351 growth arrest-specific protein 6 Proteins 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229950009580 merestinib Drugs 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- YUPQMVSYNJQULF-UHFFFAOYSA-N methyl 4-amino-2-methoxybenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1OC YUPQMVSYNJQULF-UHFFFAOYSA-N 0.000 description 1
- CIGIORHANUAMOC-UHFFFAOYSA-N methyl 7-methoxyquinoline-6-carboxylate Chemical compound COC1=C(C=C2C=CC=NC2=C1)C(=O)OC CIGIORHANUAMOC-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- JUNOWSHJELIDQP-UHFFFAOYSA-N morpholin-4-ium-3-carboxylate Chemical compound OC(=O)C1COCCN1 JUNOWSHJELIDQP-UHFFFAOYSA-N 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000029712 muscle cell homeostasis Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- QHADVLVFMKEIIP-UHFFFAOYSA-N n-[3-fluoro-4-[1-methyl-6-(1h-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide Chemical compound O=C1N(C=2C=CC(F)=CC=2)C(C)=CC=C1C(=O)NC(C=C1F)=CC=C1OC1=CC=2C=NN(C)C=2C=C1C=1C=NNC=1 QHADVLVFMKEIIP-UHFFFAOYSA-N 0.000 description 1
- MGNPLIACIXIYJE-UHFFFAOYSA-N n-fluoroaniline Chemical compound FNC1=CC=CC=C1 MGNPLIACIXIYJE-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- IPBPLHNLRKRLPJ-UHFFFAOYSA-N oxan-4-ylmethanamine Chemical compound NCC1CCOCC1 IPBPLHNLRKRLPJ-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 125000005592 polycycloalkyl group Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000001686 pro-survival effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- CQBPOPVKDNHISM-UHFFFAOYSA-N propane-1,2,3-triol;propan-2-one Chemical compound CC(C)=O.OCC(O)CO CQBPOPVKDNHISM-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- LETVJWLLIMJADE-UHFFFAOYSA-N pyridazin-3-amine Chemical compound NC1=CC=CN=N1 LETVJWLLIMJADE-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- SOGXYCNKQQJEED-UHFFFAOYSA-N tert-butyl 2-(aminomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1CN SOGXYCNKQQJEED-UHFFFAOYSA-N 0.000 description 1
- NKYPLWFWPDZVGZ-UHFFFAOYSA-N tert-butyl 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]piperidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1C(CCCC1)N1N=CC(=C1)B1OC(C(O1)(C)C)(C)C NKYPLWFWPDZVGZ-UHFFFAOYSA-N 0.000 description 1
- XTDXZSGSIMLARD-UHFFFAOYSA-N tert-butyl 2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC=CC=C1 XTDXZSGSIMLARD-UHFFFAOYSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
- POHWAQLZBIMPRN-UHFFFAOYSA-N tert-butyl n-(3-aminopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCN POHWAQLZBIMPRN-UHFFFAOYSA-N 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- RSPCKAHMRANGJZ-UHFFFAOYSA-N thiohydroxylamine Chemical compound SN RSPCKAHMRANGJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Definitions
- the present invention relates to a polysubstituted pyridone derivative, a process for the preparation thereof, a pharmaceutical composition containing the same, and its use as an Axl/c-MET inhibitor, particularly in the treatment of cancer.
- Receptor tyrosine kinases are multidomain transmembrane proteins that function as sensors for extracellular receptor ligands in cells. When the ligand binds to the receptor, the receptor is dimerized on the surface of the cell membrane and activates the kinase domain within the membrane, resulting in phosphorylation of tyrosine and further activation of a cascade of signaling pathways downstream. To date, nearly 60 receptor tyrosine kinases have been found in the human genome, which extensively regulate the cellular metabolic processes, including survival, growth, differentiation, proliferation, adhesion, and death.
- the TAM family of receptor tyrosine kinases has three members, Axl, Mer, and Tyro-3, which regulate a variety of cytological responses including cell survival, differentiation, migration, and adhesion. Studies have shown that the signaling of receptor TAM also controls vascular smooth muscle homeostasis, platelet function, microthrombus stability and erythrocyte formation. The receptor TAM also plays a key role in immunity and inflammation. It promotes phagocytosis of apoptotic cells and stimulates the differentiation of NK cells.
- Axl is a member of the TAM family of receptor tyrosine kinases. Among the three members, Axl and Tyro-3 have the most similar gene structure, while Axl and Mer have the most similar tyrosine kinase domain amino acid sequence.
- Axl is an important regulator of cell survival, proliferation, aggregation, migration and adhesion. Axl is widely expressed in cells and organs such as monocytes, macrophages, platelets, endothelial cells, cerebellum, heart, skeletal muscle, liver and kidney. In the study of many cancer cells, the Axl gene in hematopoietic cells, mesenchymal cells and endothelial cells is overexpressed or ectopically expressed. Overexpression of Axl is particularly prominent in all types of leukemia and most solid tumors. Moreover, Axl is more highly expressed in metastatic or malignant tumors than normal tissues or primary tumors, and its high expression is closely related to poor clinical treatment.
- Axl is involved in drug resistance caused by different mechanisms in a variety of tumor cells, and overexpression of Axl kinase has become an important marker of cancer drug resistance in cancer patients. Inhibition of Axl receptor tyrosine kinase can reduce the activation of pro-survival signals of tumor cells, block tumor invasion, and increase the sensitivity of targeted drug therapy and chemoradiotherapy. Therefore, Axl is an effective target for cancer treatment.
- tyrosine kinase inhibitors such as Cabozinidinib, Foretinib, Merestinib, Crizotinib, etc.
- Cabozinidinib Foretinib
- Merestinib Merestinib
- Crizotinib etc.
- Axl kinase inhibitor activity they are multi-target molecules, Not selective.
- BGB324 The only clinical candidate for Axl selectivity in the world is BGB324, which is undergoing multiple clinical phase II trials. Therefore, there is currently no new drug for Axl inhibitors for patients.
- c-MET is a member of the transmembrane tyrosine kinase receptor (RTKs) family with autonomous phosphorylation activity.
- the c-MET receptor contains a tyrosine residue that regulates the activity of the enzyme in the tyrosine kinase catalytic domain of the cell, forming a docking site for several signaling proteins, which in turn leads to a biological response.
- c-MET was first isolated from cell lines derived from human osteosarcoma, primarily on epithelial cells. During embryonic development and adulthood, many organ epithelial cells express c-MET receptors on the surface, including liver, pancreas, prostate, kidney, muscle, and bone marrow.
- HGF is the only ligand for c-MET.
- c-MET When c-MET binds to it, it triggers receptor dimerization, thereby activating tyrosine kinase in the c-MET cytoplasmic protein kinase domain, causing autophosphorylation of c-MET carboxy terminal tyrosine (Tyrl349, Tyrl356) Chemical.
- c-MET activates the recruitment of the adaptor proteins Gabl and Grb2, activates Shp2, Ras and ERK/MAPK, and multiple effector proteins in the cytoplasm are recruited to the phosphorylated carboxy terminus and rapidly phosphorylated, resulting in activation of multiple signaling pathways within the cell, such as PI3K/AKT, Ras-Rac/Rho, MAPK and STAT3 pathways promote various biological functions such as cell deformation, proliferation, anti-apoptosis, cell separation, exercise and invasion.
- the normal HGF/c-MET signaling pathway participates in various physiological processes in different cells and different stages of cell differentiation, such as controlling cell migration during embryonic development and repairing after tissue damage.
- abnormal c-MET disorders include overexpression, sustained activation of constituent kinases, gene amplification, by HGF paracrine and autocrine activation, c-MET mutations, and subsequent changes.
- Abnormal HGF/c-MET signaling pathway plays a very important role in tumorigenesis and can induce tumor growth, invasion, drug resistance and survival. Therefore, effective inhibition of HGF/c-MET signaling pathways in tumor cells will have a significant effect on a variety of cancers.
- the present inventors have developed new AxL/c-MET inhibitors. It can be used alone or in combination with other active drugs, providing a broad prospect for the treatment of cancer.
- the inventors have deliberately studied and designed a series of polysubstituted pyridone derivatives, and intensive studies have shown that such compounds can be used as effective Axl/c-MET inhibitors. It can be used alone or in combination with other active drugs for the treatment of cancer, in particular solid tumors or hematological tumors with high expression of Axl/c-MET.
- the present invention relates to a compound of the formula (I) or a racemate, a racemate, an enantiomer, a diastereomer thereof, or a mixture thereof, or a pharmaceutically acceptable form thereof salt,
- W and V are each independently selected from CH, CF or N;
- R a is selected from -OR 1 , -SR 1 or -NR 1 R 2 ;
- R 1 and R 2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, said alkyl, alkenyl, alkynyl, cycloalkyl And a heterocyclic group, an aryl group and a heteroaryl group are optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl Substituting one or more groups of a heterocyclic group, an aryl group, or a heteroaryl group;
- R a is -NR 1 R 2
- R 1 and R 2 together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic ring, which is optionally further selected from the group consisting of halogen, amino, nitro, cyano Substituting one or more groups of a group, a hydroxyl group, a thiol group, a carboxyl group, an ester group, an oxo group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group;
- R 3 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aromatic
- the base and heteroaryl are optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl Substituting one or more groups of a heteroaryl group;
- R a is -NR 1 R 2
- R 1 and R 2 together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic ring
- R 3 is bonded to the nitrogen-containing heterocyclic ring to further form a fused heterocyclic ring
- said nitrogen heterocycle is optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, thiol, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, Substituting one or more groups of a heteroaryl group;
- R 4 is selected from an aryl group, a heteroaryl group or an alkynyl group, which is optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, thiol, carboxyl, ester, Substituting one or more groups of oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
- R 4 when R 4 is aryl or heteroaryl, R a is bonded to R 4 to form a heterocyclic ring fused to R 4 , which is optionally further selected from the group consisting of halogen, amino, nitro, cyano, Substituting one or more groups of a hydroxyl group, a mercapto group, a carboxyl group, an ester group, an oxo group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group;
- R 5 is selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or OR 6 , said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, The aryl and heteroaryl are optionally further substituted with one or more groups selected from the group Q;
- Q is selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
- the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl group is optionally further selected from the group consisting of halogen, nitro, cyano, hydroxy, decyl, oxo, alkyl, cycloalkyl, Heterocyclyl, aryl, heteroaryl, -OR b , -O(CH 2 ) m OR b , -OC(O)R b , -C(O)OR b , -C(O)NR b R c , -NHC(O)R b , -S(O)R b , -S(O) 2 R b ,
- R 6 is selected from the group consisting of alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl; said alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl Further selected from the group consisting of halogen, nitro, cyano, hydroxy, decyl, oxo, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR b , -O(CH 2 ) m OR b , -OC(O)R b , -C(O)OR b , -C(O)NR b R c , -NHC(O)R b , -S(O)R b , -S(O) 2 R b , -S(O)NR b R c , -NR b R c , -NR b R c , -NR b R
- R b and R c are each independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl And the heteroaryl group is optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl Substituting one or more groups of a heteroaryl group;
- R b and R c together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic group, which is optionally further selected from the group consisting of halogen, amino, nitro, cyano, oxo, hydroxy, decyl Substituting one or more groups of a carboxyl group, an ester group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group;
- R 7 is selected from the group consisting of hydrogen, halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl
- the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl group is optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, thiol, carboxy, ester, and oxygen. Substituting one or more groups of a substituent, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group;
- n is an integer from 1 to 6;
- n is an integer from 1 to 4.
- each H atom of the compound of formula (I) may optionally be independently replaced by a D atom.
- the compound of the formula (I) according to the invention or a racemate, a racemate, an enantiomer thereof, a diastereomer thereof, Or a mixture thereof, or a pharmaceutically acceptable salt thereof,
- R a is selected from -NR 1 R 2 ;
- R 1 and R 2 are as defined by the formula (I).
- the compound of the formula (I) according to the invention or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof in another preferred embodiment of the invention, or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof,
- R 1 and R 2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, said alkyl, alkenyl, alkynyl, cycloalkyl And a heterocyclic group, an aryl group and a heteroaryl group are optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl Substituting one or more groups of a heterocyclic group, an aryl group, or a heteroaryl group;
- R a is -NR 1 R 2
- R 1 and R 2 together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic ring, which is optionally further selected from the group consisting of halogen, amino, nitro, cyano Substituting one or more groups of a group, a hydroxyl group, a thiol group, a carboxyl group, an ester group, an oxo group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group;
- the nitrogen-containing heterocyclic ring is preferably a 4- to 7-membered nitrogen-containing heterocyclic ring, more preferably the following heterocyclic ring:
- R 3 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aromatic
- the base and heteroaryl are optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl Substituting one or more groups of a heteroaryl group.
- the compound of the formula (I) according to the invention or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof in another preferred embodiment of the invention, or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof,
- R a is selected from -NR 1 R 2 ;
- R 1 or R 2 is bonded to R 3 to form a nitrogen-containing heterocyclic ring fused to a pyridone ring, which is optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, Substituting one or more groups of a carboxyl group, an ester group, an oxo group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group;
- R 1 and R 2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, said alkyl, alkenyl, alkynyl, cycloalkyl And a heterocyclic group, an aryl group and a heteroaryl group are optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl Substituting one or more groups of a heterocyclic group, an aryl group, or a heteroaryl group;
- R 3 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aromatic
- the base and heteroaryl are optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl Substituting one or more groups of a heteroaryl group;
- the nitrogen-containing heterocyclic ring fused to the pyridone ring is preferably a 6- or 12-membered nitrogen-containing heterocyclic ring, more preferably the following nitrogen-containing heterocyclic ring:
- the compound of the formula (I) according to the invention or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof in another preferred embodiment of the invention, or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof,
- R a is selected from -NR 1 R 2 ;
- R 1 and R 2 together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic ring, and R 3 is bonded to the nitrogen-containing heterocyclic ring to further form a fused heterocyclic ring, which is optionally further selected from the group consisting of halogen, amino, Substituting one or more groups of nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
- R 1 and R 2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, said alkyl, alkenyl, alkynyl, cycloalkyl And a heterocyclic group, an aryl group and a heteroaryl group are optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl Substituting one or more groups of a heterocyclic group, an aryl group, or a heteroaryl group;
- R 3 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aromatic
- the base and heteroaryl are optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl Substituting one or more groups of a heteroaryl group;
- the fused heterocyclic ring is preferably a 10-12 membered fused heterocyclic ring, more preferably:
- the compound of the formula (I) according to the invention or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof which is a compound of the formula (II) or a mesogen, a racemate, an enantiomer, a diastereomer thereof, or a form of the mixture, or a pharmaceutically acceptable salt thereof,
- Y is selected from CH or N;
- q is an integer from 1 to 4.
- W, V, R a , R 3 , R 4 , R 7 , Q, n are as defined in the general formula (I).
- the compound of the formula (I) according to the invention or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof in another preferred embodiment of the invention, or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof,
- R 4 is selected from 5- to 6-membered aryl or heteroaryl, or alkynyl, and the aryl, heteroaryl, alkynyl group is optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, Substituting one or more groups of a carboxyl group, an ester group, an oxo group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group;
- the aryl, heteroaryl, alkynyl group is preferably:
- the compound of the formula (I) according to the invention or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof which is a compound of the formula (III) or a racemate, a racemate, an enantiomer, a diastereomer thereof, or a form of the mixture, or a pharmaceutically acceptable salt thereof,
- Y is selected from CH or N;
- R 8 is selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl;
- p is an integer from 1 to 4.
- q is an integer from 1 to 4.
- W, V, R a , R 3 , R 7 , Q, n are as defined in the general formula (I).
- the compound of the formula (I) according to the invention or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof which is a compound of the formula (IV) or a mesogen, racemate, enantiomer, diastereomer thereof, or a form of the mixture, or a pharmaceutically acceptable salt thereof,
- Y is selected from CH or N;
- R 8 is selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl;
- Q is selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl;
- the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl group is optionally further selected from the group consisting of halogen, nitro, cyano, hydroxy, decyl, oxo, alkyl, cycloalkyl, Heterocyclyl, aryl, heteroaryl, -OR b , -O(CH 2 ) m OR b , -OC(O)R b , -C(O)OR b , -C(O)NR b R c , -NHC(O)R b , -S(O)R b , -S(O) 2 R b ,
- Q' is selected from -NR b R c ;
- R b and R c are each independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl And the heteroaryl group is optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl Substituting one or more groups of a heteroaryl group;
- R b and R c together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic group, which is optionally further selected from the group consisting of halogen, amino, nitro, cyano, oxo, hydroxy, decyl Substituting one or more groups of a carboxyl group, an ester group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group;
- p is an integer from 1 to 4.
- W, V, R a , R 3 , R 7 , m, n are as defined in the general formula (I).
- the compound of the formula (I) according to the invention or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof in another preferred embodiment of the invention, or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof,
- Q is selected from aryl or heteroaryl; the aryl or heteroaryl is optionally further selected from the group consisting of halogen, alkyl, cycloalkyl, heterocyclyl, -OR b , -O(CH 2 ) m OR b Substituted by one or more groups;
- R b is selected from the group consisting of hydrogen, alkyl and cycloalkyl, wherein the alkyl and cycloalkyl are optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo. Substituting one or more groups of a cycloalkyl group or a heterocyclic group;
- n 1 to 6.
- the compound of the formula (I) according to the invention or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof in another preferred embodiment of the invention, or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof,
- R a is selected from -NR 1 R 2 ;
- R 1 or R 2 is bonded to R 4 to form a heterocyclic ring fused to R 4 , preferably a 6-membered heterocyclic ring, which is optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy Substituting one or more groups of an ester group, an oxo group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group;
- R 1 and R 2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, said alkyl, alkenyl, alkynyl, cycloalkyl And a heterocyclic group, an aryl group and a heteroaryl group are optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl Substituting one or more groups of a heterocyclic group, an aryl group, or a heteroaryl group;
- R 3 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aromatic
- the base and heteroaryl are optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl, carboxy, ester, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl Substituting one or more groups of a heteroaryl group.
- the compound of the formula (I) according to the invention or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof in another preferred embodiment of the invention, or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof,
- R 5 is OR 6 or SR 6 ;
- R 6 is as defined in the general formula (I);
- the compound of the formula (I) according to the invention or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof in another preferred embodiment of the invention, or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof,
- R 6 is selected from the group consisting of aryl and heteroaryl; the aryl and heteroaryl are optionally further selected from the group consisting of halogen, hydroxy, thiol, oxo, alkyl, cycloalkyl, heterocyclyl, aryl, hetero Substituting one or more groups of aryl, -OR b , -O(CH 2 ) m OR b , -NR b R c ;
- R b and R c are each independently selected from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, wherein the alkyl, cycloalkyl, optionally further selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, decyl Substituting one or more groups of a carboxyl group, an ester group, an oxo group, a cycloalkyl group, or a heterocyclic group;
- R b and R c together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic group, which is optionally further selected from the group consisting of halogen, amino, nitro, cyano, oxo, hydroxy, decyl Substituting one or more groups of a carboxyl group, an ester group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group;
- n 1 to 6.
- the compound of the formula (I) according to the invention or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof in another preferred embodiment of the invention, or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof,
- R 7 is selected from the group consisting of hydrogen, halogen, alkyl, and the alkyl group is optionally further substituted with one or more halogens;
- n 1 or 2.
- the compound of the formula (I) according to the invention or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof in another preferred embodiment of the invention, or a mesogen, racemate, enantiomer or diastereomer thereof Or a mixture thereof, or a pharmaceutically acceptable salt thereof,
- R 5 is the following group:
- Exemplary compounds of the invention include, but are not limited to, the following compounds:
- Another aspect of the invention provides a compound of the formula (I) or a racemate, a racemate, an enantiomer, a diastereomer thereof, or a mixture thereof, or A method for preparing a medicinal salt, comprising the steps of:
- NR 3 -6-(ethoxycarbonyl)-5-R 4 -4-oxo-1,4-dihydropyridine-3-arylamide (Ig) is first subjected to ester hydrolysis, and then to R 1 R 2 NH is subjected to amidation reaction to obtain a compound of the formula (I) via a two-step process;
- R a is selected from -OR 1 when 1 or -SR
- the NR 3 -6-(ethoxycarbonyl)-5-R 4 -4-oxo-1,4-dihydropyridine-3-arylamide (Ig) is first subjected to ester hydrolysis to obtain the acid (Ig'). Further reacting with an alcohol or a thiol under the action of EDCI to obtain a compound of the formula (I);
- R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , W, V, n are as defined in the formula (I).
- the invention further provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the formula (I) according to the invention or a racemate, a racemate, an enantiomer thereof, a diastereomer Or a mixture thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
- the pharmaceutical composition may further comprise another therapeutically active ingredient, preferably another therapeutically active ingredient, preferably a rectal cancer, an intestinal cancer, a pancreatic cancer, a breast cancer, a prostate cancer, Esophageal cancer, gastric cancer, blood cancer, lung cancer, liver cancer, thyroid cancer, sarcoma, brain cancer, skin cancer, head and neck cancer, nasopharyngeal cancer, ovarian cancer, cervical cancer, bladder cancer and kidney cancer, more preferably blood cancer, lung cancer, breast cancer, Pancreatic cancer and stomach cancer.
- another therapeutically active ingredient preferably another therapeutically active ingredient, preferably a rectal cancer, an intestinal cancer, a pancreatic cancer, a breast cancer, a prostate cancer, Esophageal cancer, gastric cancer, blood cancer, lung cancer, liver cancer, thyroid cancer, sarcoma, brain cancer, skin cancer, head and neck cancer, nasopharyngeal cancer, ovarian cancer, cervical cancer, bladder cancer and kidney cancer, more preferably blood cancer, lung cancer, breast cancer, Pan
- the present invention also relates to a process for the preparation of the above composition, which comprises the compound of the formula (I) or a racemate, a racemate, an enantiomer thereof, a diastereomer thereof, Or a mixture thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, is admixed with a pharmaceutically acceptable carrier, diluent or excipient.
- the invention further provides a compound of the formula (I) according to the invention or a racemate, a racemate, an enantiomer, a diastereomer thereof, or a mixture thereof Or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, for use in the preparation of an Axl/c-MET inhibitor.
- the invention further provides a compound of the formula (I) according to the invention or a racemate, a racemate, an enantiomer, a diastereomer thereof, or a mixture thereof Or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, for use in the manufacture of a medicament for treating cancer.
- the cancer is preferably rectal cancer, intestinal cancer, pancreatic cancer, breast cancer, prostate cancer, esophageal cancer, gastric cancer, blood cancer, lung cancer, liver cancer, thyroid cancer, sarcoma, brain cancer, skin cancer, head and neck cancer, nasopharyngeal cancer, ovarian cancer.
- cervical cancer, bladder cancer and kidney cancer more preferably blood cancer, lung cancer, breast cancer, pancreatic cancer and gastric cancer.
- the cancer is preferably rectal cancer, intestinal cancer, pancreatic cancer, breast cancer, prostate cancer, esophageal cancer, gastric cancer, blood cancer, lung cancer, liver cancer, thyroid cancer, sarcoma, brain cancer, skin cancer, head and neck cancer, nasopharyngeal cancer, Ovarian cancer, cervical cancer, bladder cancer, and kidney cancer, and more preferably, blood cancer, lung cancer, breast cancer, pancreatic cancer, and stomach cancer.
- the invention further provides a compound of the formula (I) according to the invention or a racemate, a racemate, an enantiomer, a diastereomer thereof, or a mixture thereof Or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, which is used as an Axl/c-MET inhibitor.
- the invention further provides a compound of the formula (I) according to the invention or a racemate, a racemate, an enantiomer, a diastereomer thereof, or a mixture thereof Or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, which is used as a medicament for treating cancer;
- the cancer is preferably rectal cancer, intestinal cancer, pancreatic cancer, breast cancer, prostate cancer, esophageal cancer, gastric cancer, blood cancer, Lung cancer, liver cancer, thyroid cancer, sarcoma, brain cancer, skin cancer, head and neck cancer, nasopharyngeal cancer, ovarian cancer, cervical cancer, bladder cancer, and kidney cancer, and more preferably, blood cancer, lung cancer, breast cancer, pancreatic cancer, and stomach cancer.
- the cancer is preferably rectal cancer, intestinal cancer, pancreatic cancer, breast cancer, prostate cancer, esophageal cancer, gastric cancer, blood cancer, lung cancer, liver cancer, thyroid cancer, sarcoma, brain cancer, skin cancer, head and neck cancer, nasopharyngeal Cancer, ovarian cancer, cervical cancer, bladder cancer, and kidney cancer, and more preferably, blood cancer, lung cancer, breast cancer, pancreatic cancer, and stomach cancer.
- a method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) according to the invention or a mesogen, racemate, enantiomer thereof a form, a mixture of diastereomers, or a mixture thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, preferably a rectal cancer, an intestinal cancer, a pancreatic cancer, a breast cancer, a prostate cancer, an esophageal cancer , gastric cancer, blood cancer, lung cancer, liver cancer, thyroid cancer, sarcoma, brain cancer, skin cancer, head and neck cancer, nasopharyngeal cancer, ovarian cancer, cervical cancer, bladder cancer and kidney cancer, more preferably blood cancer, lung cancer, breast cancer, pancreatic cancer And stomach cancer.
- a rectal cancer an intestinal cancer, a pancreatic cancer, a breast cancer, a prostate cancer, an esophageal cancer , gastric cancer, blood cancer, lung cancer
- a method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) according to the invention or a mesogen, racemate, enantiomer thereof , a diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition therewith, and another therapeutically active ingredient, wherein the other therapeutically active ingredient
- the cancer is preferably rectal cancer, intestinal cancer, pancreatic cancer, breast cancer, prostate cancer, esophageal cancer, gastric cancer, blood cancer, lung cancer, liver cancer, thyroid cancer, sarcoma, brain cancer , skin cancer, head and neck cancer, nasopharyngeal cancer, ovarian cancer, cervical cancer, bladder cancer and kidney cancer, more preferably blood cancer, lung cancer, breast cancer, pancreatic cancer and gastric cancer.
- the compound of the formula (I) of the present invention can form a pharmaceutically acceptable acid addition salt with an acid according to a conventional method in the art to which the present invention pertains.
- the acid includes inorganic acids and organic acids, and acceptable inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, etc.
- Acceptable organic acids include methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, Naphthalene disulfonic acid, acetic acid, propionic acid, lactic acid, trifluoroacetic acid, maleic acid, citric acid, fumaric acid, oxalic acid, tartaric acid, benzoic acid, and the like.
- the compound of the formula (I) of the present invention can form a pharmaceutically acceptable base addition salt with a base according to a conventional method in the art to which the present invention pertains.
- the base includes an inorganic base and an organic base, and acceptable organic bases include diethanolamine, ethanolamine, N-methylglucamine, triethanolamine, tromethamine, etc., and acceptable inorganic bases include aluminum hydroxide and hydroxide. Calcium, potassium hydroxide, sodium carbonate and sodium hydroxide.
- the pharmaceutical composition of the present invention includes any one or more of the compounds of the present invention (or a pharmaceutically acceptable salt, solvate, hydrate, prodrug or derivative thereof) and optionally a pharmaceutically acceptable Carrier. In certain embodiments, these compositions optionally further comprise one or more additional therapeutic agents. Alternatively, the compounds of the invention may be administered to a patient in need thereof in combination with one or more other therapeutic agents. It will also be understood that certain compounds of the invention may exist in free form or, where appropriate, in the form of their pharmaceutically acceptable salts for therapeutic use.
- the pharmaceutical compositions of the present invention also include a pharmaceutically acceptable carrier.
- the carrier includes any or all solvents, diluents, or other liquid carriers, dispersion or suspending adjuvants, surfactants, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricating agents Agents, etc., which are adjusted to the particular dosage form desired.
- Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers for formulating pharmaceutical compositions, as well as known techniques for their preparation.
- any conventional carrier medium is contemplated to be within the scope of the invention unless it is incompatible with the compounds of the invention, for example, by producing any undesirable biological effects or interacting in a deleterious manner with any other component of the pharmaceutical composition.
- materials that can be used as pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethyl Cellulose and cellulose acetate; powdered tragacanth; maltose; gelatin; talc; excipients such as cocoa butter and suppository wax; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and Soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide
- the compounds of the invention can be administered to a patient by a variety of routes of administration. These routes of administration include, but are not limited to, oral, sublingual, subcutaneous, intravenous, nasal, topical, dermal, intraperitoneal, intramuscular, pulmonary, and the like.
- compositions containing the active ingredient may be in the form of solids, semi-solids, liquids and aerosols, for example, tablets, granules, capsules, powders, liquids, suspensions, suppositories, and the like. It can also be administered in a sustained release manner, for example, by a long-acting injection, an osmotic pump, a pill, a patch, or the like.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound is mixed with at least one inert pharmaceutically acceptable excipient or carrier, such as a) filler or filler, such as starch, lactose, sucrose, glucose, mannitol and silicic acid, b) viscous Mixtures such as carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and gum arabic, c) humectants such as glycerin, d) disintegrants such as agar, calcium carbonate, potato or tapioca starch , alginic acid, certain silicates and sodium carbonate, e) solution retarding agents, such as paraffin, f) absorption accelerators, such as quaternary ammonium compounds, g) wetting agents, such as cetyl alcohol and mono-hard Glycerol, h) absorbents such as kaolin and bentonite,
- Solid compositions of a similar type may also be employed as fillers in filling soft or hard gelatin capsules using excipients such as lactose and high molecular weight polyethylene glycols.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells (e.g., enteric coatings and other coatings well known in the pharmaceutical formulation art). It may optionally comprise an opacifying agent, and may also be a composition which is released only, or preferably in certain parts of the intestinal tract, optionally releasing the active ingredient in a delayed manner.
- coatings and shells e.g., enteric coatings and other coatings well known in the pharmaceutical formulation art.
- It may optionally comprise an opacifying agent, and may also be a composition which is released only, or preferably in certain parts of the intestinal tract, optionally releasing the active ingredient in a delayed manner.
- useful embedding compositions include polymeric materials and waxes.
- Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage form may contain inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzoic acid Benzyl ester, propylene glycol, 1,3-butanediol, dimethylformamide, oil (especially cottonseed, groundnut (peanut), corn, germ, olive, ramie and sesame oil), glycerin, tetrahydrofurfuryl alcohol, Polyethylene glycol and sorbitan fatty acid esters, and mixtures thereof.
- the oral compositions may also include adjuvants such
- Injectable preparations may be formulated in accordance with the prior art using suitable dispersion or wetting agents and suspensions.
- the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a non-toxic parenterally acceptable diluent or solvent, for example, a solution in 1,3-butanediol.
- Acceptable carriers or solvents include water, Ringer's solution, and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspension.
- any bland fixed oil may be employed, including the prepared mono or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- the injectable preparation may be sterile, for example, by filtration through a bacteria-resistance filter, or by adding a bactericidal agent in the form of a sterile solid composition before use, which may be dissolved or dispersed in sterile water or other In bacteria injectable medium.
- compositions for rectal or vaginal administration are preferably suppositories which can be prepared by admixing a compound of the present invention with a suitable non- irritating excipient or carrier (for example, cocoa butter, polyethylene glycol or suppository wax) in the environment It is a solid at temperature and is a liquid at body temperature, thus melting and releasing the active compound in the rectum or vaginal cavity.
- a suitable non- irritating excipient or carrier for example, cocoa butter, polyethylene glycol or suppository wax
- the dosage of the drug to be administered depends on a variety of factors including, but not limited to, the following factors: the activity of the particular compound used, the age of the patient, the weight of the patient, the health of the patient, the conduct of the patient, the patient Diet, time of administration, mode of administration, rate of excretion, combination of drugs, and the like.
- the optimal mode of treatment such as the mode of treatment, the daily amount of the compound of the formula, or the type of pharmaceutically acceptable salt, can be verified according to conventional treatment regimens.
- the compounds or pharmaceutical compositions of the invention may be formulated and used in combination therapy, i.e., the compounds and pharmaceutical compositions may be formulated simultaneously, prior or subsequently with one or more other desired therapies or procedures. Apply.
- the particular combination of treatments (therapies or procedures) employed in the combination regimen will take into account the compatibility of the desired therapy and/or procedure, as well as the desired therapeutic effect to be achieved.
- alkyl refers to a saturated aliphatic hydrocarbon group which is a straight or branched chain group containing from 1 to 20 carbon atoms, preferably an alkyl group having from 1 to 12 carbon atoms, more preferably from 1 to 6 carbons.
- the alkyl group of the atom is a saturated aliphatic hydrocarbon group which is a straight or branched chain group containing from 1 to 20 carbon atoms, preferably an alkyl group having from 1 to 12 carbon atoms, more preferably from 1 to 6 carbons.
- Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 - dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2 -methylhexyl, 3-methylhexyl, 4-methylhexyl,
- lower alkyl groups having from 1 to 6 carbon atoms, non-limiting examples including methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl Base, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethyl Butyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl Base, 2,3-dimethylbutyl and the like.
- the alkyl group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, preferably one or more of the following groups independently selected from the group consisting of an alkane Base, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, naphthenic An oxy group, a heterocycloalkoxy group, a cycloalkylthio group, a heterocycloalkylthio group, an oxo group, a carboxyl group or a carboxylate group.
- an alkane Base alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, hetero
- alkenyl refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, such as ethenyl, 1-propenyl, 2-propenyl, 1-, 2- or 3- Butyl group and the like.
- the alkenyl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio group.
- alkynyl refers to an alkyl radical as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, such as ethynyl, propynyl, butynyl and the like.
- the alkynyl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio group.
- cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing from 3 to 20 carbon atoms, preferably from 3 to 12 carbon atoms, more preferably from 3 to 6 carbon atoms. One carbon atom.
- Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene
- a polycycloalkyl group includes a spiro ring, a fused ring, and a cycloalkyl group.
- spirocycloalkyl refers to a polycyclic group that shares a carbon atom (referred to as a spiro atom) between 5 to 20 members of a single ring, which may contain one or more double bonds, but none of the rings have a fully conjugated ⁇ electronic system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- the spirocycloalkyl group is classified into a monospirocycloalkyl group, a bispirocycloalkyl group or a polyspirocycloalkyl group, preferably a monospirocycloalkyl group and a bispirocycloalkyl group, depending on the number of common spiro atoms between the rings.
- spirocycloalkyl groups include:
- fused cycloalkyl refers to 5 to 20 members, and each ring in the system shares an all-carbon polycyclic group of an adjacent pair of carbon atoms with other rings in the system, wherein one or more of the rings may contain one or Multiple double bonds, but none of the rings have a fully conjugated ⁇ -electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- fused cycloalkyl groups include:
- bridged cycloalkyl refers to an all-carbon polycyclic group of 5 to 20 members, any two rings sharing two carbon atoms which are not directly bonded, which may contain one or more double bonds, but none of the rings have complete Conjugate ⁇ -electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members. Depending on the number of constituent rings, it may be classified into a bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl group, preferably a bicyclic ring, a tricyclic ring or a tetracyclic ring, and more preferably a bicyclic ring or a tricyclic ring.
- bridged cycloalkyl groups include:
- the cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring to which the parent structure is attached is a cycloalkyl group, non-limiting examples include indanyl, tetrahydronaphthalene Base, benzocycloheptyl and the like.
- the cycloalkyl group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio a heterocycloalkylthio group, an oxo group, a carboxyl group or a carboxylate group.
- heterocyclyl or “heterocycle” refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing from 3 to 20 ring atoms wherein one or more ring atoms are selected from the group consisting of nitrogen and oxygen. Or a hetero atom of S(O) m (where m is an integer of 0 to 2), but excluding the ring moiety of -OO-, -OS- or -SS-, the remaining ring atoms being carbon.
- ring atoms Preferably comprising from 3 to 12 ring atoms, wherein from 1 to 4 are heteroatoms; most preferably from 3 to 8 ring atoms, wherein from 1 to 3 are heteroatoms; most preferably from 5 to 7 ring atoms, wherein 1 to 2 or 1 to 3 are heteroatoms.
- monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidine.
- the group, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl and the like are preferably 1, 2, 5-oxadiazolyl, pyranyl or morpholinyl.
- Polycyclic heterocyclic groups include spiro, fused, and bridged heterocyclic groups.
- spiroheterocyclyl or “spiroheterocycle” refers to a polycyclic heterocyclic group in which one atom (called a spiro atom) is shared between 5 to 20 members of a single ring, wherein one or more ring atoms are selected from nitrogen. a hetero atom of oxygen or S(O) m (where m is an integer from 0 to 2), and the remaining ring atoms are carbon. It may contain one or more double bonds, but none of the rings have a fully conjugated pi-electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- the spiroheterocyclyl group is classified into a monospiroheterocyclic group, a dispiroheterocyclic group or a polyspirocyclic group according to the number of shared spiro atoms between the ring and the ring, and is preferably a monospiroheterocyclic group and a dispiroheterocyclic group. More preferably, it is 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6-membered monospiroheterocyclic group.
- Non-limiting examples of spiroheterocyclyl groups include:
- fused heterocyclic refers to 5 to 20 members, each ring of the system sharing an adjacent pair of atomic polycyclic heterocyclic groups with one or more of the other rings in the system, one or more A ring may contain one or more double bonds, but none of the rings have a fully conjugated ⁇ -electron system in which one or more ring atoms are selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2) a hetero atom, the remaining ring atoms being carbon. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- fused heterocyclic groups include:
- bridge heterocyclyl or “bridge heterocycle” refers to a polycyclic heterocyclic group of 5 to 14 members, any two rings sharing two atoms which are not directly bonded, which may contain one or more double bonds, but None of the rings have a fully conjugated ⁇ -electron system in which one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2) and the remaining ring atoms are carbon. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- bridge heterocyclic groups include:
- the heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring to which the parent structure is attached is a heterocyclic group, non-limiting examples of which include:
- the heterocyclic group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio a heterocycloalkylthio group, an oxo group, a carboxyl group or a carboxylate group.
- aryl refers to a 6 to 14 membered all-carbon monocyclic or fused polycyclic ring (ie, a ring that shares a pair of adjacent carbon atoms) having a conjugated ⁇ -electron system, preferably 6 to 10 members, such as benzene. Base and naphthyl. More preferred is phenyl.
- the aryl ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring to which the parent structure is attached is an aryl ring, non-limiting examples of which include:
- the aryl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle An alkylthio group, a carboxyl group or a carboxylate group.
- heteroaryl refers to a heteroaromatic system containing from 1 to 4 heteroatoms, from 5 to 14 ring atoms, wherein the heteroatoms are selected from the group consisting of oxygen, sulfur and nitrogen.
- the heteroaryl group is preferably 5 to 10 members, and has 1 to 3 hetero atoms; more preferably 5 or 6 members, and 1 to 2 hetero atoms; preferably, for example, imidazolyl, furyl, thienyl, thiazolyl, pyridyl An oxazolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazinyl, etc., preferably imidazolyl, thiazolyl, pyrazolyl or pyrimidinyl, thiazolyl; more selective Pyrazolyl or thiazolyl.
- the heteroaryl ring may be fused to an aryl, hetero
- the heteroaryl group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio a heterocycloalkylthio group, a carboxyl group or a carboxylate group.
- alkoxy refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl is as defined above.
- alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
- the alkoxy group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio a heterocycloalkylthio group, a carboxyl group or a carboxylate group.
- haloalkyl refers to an alkyl group substituted by one or more halogens, wherein alkyl is as defined above.
- haloalkoxy refers to an alkoxy group substituted by one or more halogens, wherein alkoxy is as defined above.
- hydroxyalkyl refers to an alkyl group substituted with a hydroxy group, wherein alkyl is as defined above.
- hydroxy refers to an -OH group.
- halogen means fluoro, chloro, bromo or iodo.
- amino means -NH 2.
- cyano refers to -CN.
- nitro refers to -NO 2 .
- mercapto refers to -SH.
- ester group refers to -C(O)O(alkyl) or -C(O)O(cycloalkyl), wherein alkyl and cycloalkyl are as defined above.
- acyl refers to a compound containing a -C(O)R group, wherein R is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl.
- sulfonic acid group refers to -S(O) 2 OH.
- sulfonate group refers to -S (O) 2 O (alkyl), or -S (O) 2 O (cycloalkyl), wherein alkyl and cycloalkyl are as defined above.
- heterocyclic group optionally substituted by an alkyl group means that an alkyl group may be, but not necessarily, present, and the description includes the case where the heterocyclic group is substituted with an alkyl group and the case where the heterocyclic group is not substituted with an alkyl group.
- Substituted refers to one or more hydrogen atoms in the group, preferably up to 5, more preferably 1 to 3, hydrogen atoms, independently of each other, substituted by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art will be able to determine (by experiment or theory) substitutions that may or may not be possible without undue effort. For example, an amino group or a hydroxyl group having a free hydrogen may be unstable when combined with a carbon atom having an unsaturated (e.g., olefinic) bond.
- “Pharmaceutical composition” means a mixture comprising one or more of the compounds described herein, or a physiologically/pharmaceutically acceptable salt or prodrug thereof, and other chemical components, as well as other components such as physiological/pharmaceutically acceptable carriers. And excipients.
- the purpose of the pharmaceutical composition is to promote the administration of the organism, which facilitates the absorption of the active ingredient and thereby exerts biological activity.
- “Pharmaceutically acceptable salt” refers to a salt of a compound of the invention which is safe and effective for use in a mammal and which possesses the desired biological activity.
- the present invention adopts the following technical solutions.
- Step 1 Ethyl acetoacetate and N,N-dimethylformamide dimethyl acetal are directly condensed at room temperature to obtain (Z)-2-((dimethylamino)methylene)-3- Ethyl oxobutyrate (Ia);
- Step 2 (Z)-2-((Dimethylamino)methylene)-3-oxobutanoate ethyl ester (Ia) is reacted with strong sodium hydride in anhydrous tetrahydrofuran to form an enol sodium salt intermediate And then undergoing a cyclization reaction with diethyl oxalate to obtain diethyl 4-oxo-4H-pyran-2,5-dicarboxylate (Ib);
- Step 3 Diethyl 4-oxo-4H-pyran-2,5-dicarboxylate (Ib) and amine (R 3 NH 2 ) are subjected to an addition-condensation reaction to obtain NR 3 -4-oxo- Diethyl 1,4-dihydropyridine-2,5-dicarboxylate (Ic);
- Step 4 NR 3 -1-4-oxo-1,4-dihydropyridine-2,5-dicarboxylic acid diethyl ester (Ic) is brominated by N-bromosuccinimide (NBS). NR 3 -3-bromo-4-oxo-1,4-dihydropyridine-2,5-dicarboxylic acid diethyl ester (Id) was obtained.
- Step 5 NR 3 -3-bromo-4-oxo-1,4-dihydropyridine-2,5-dicarboxylic acid diethyl ester (Id) and the corresponding boric acid by Suzuki coupling reaction (potassium carbonate as a base, Pd(dppf)Cl 2 is a catalyst, dioxane/water is a mixed solvent, and the reaction temperature is 80 ° C), and NR 3 -3-R 4 -4-oxo-1,4-dihydropyridine-2 is obtained.
- 5-dicarboxylic acid diethyl ester (Ie) 5-dicarboxylic acid diethyl ester (Ie);
- Step 6 Selective hydrolysis of NR 3 -3-R 4 -4-oxo-1,4-dihydropyridine-2,5-dicarboxylate diethyl ester (Ie) under the action of sodium hydroxide to obtain NR 3-6- (ethoxycarbonyl) -5-R 4 -4- oxo-1,4-dihydropyridine-3-carboxylic acid (the If);
- Step 7 NR 3 -6-(ethoxycarbonyl)-5-R 4 -4-oxo-1,4-dihydropyridine-3-carboxylic acid (If) with aromatic amine (Ih) via HATU and N , N-diisopropylethylamine (DIPEA) was subjected to amidation to give NR 3 -6-(ethoxycarbonyl)-5-R 4 -4-oxo-1,4-dihydropyridine-3- Aromatic amide (Ig);
- Step 8 NR 3 -6-(ethoxycarbonyl)-5-R 4 -4-oxo-1,4-dihydropyridine-3-arylamide (Ig) can be directly amine with R 1 R 2 NH Transesterification to obtain a compound of the formula (I); or a two-step process of amidation with a pre-ester group followed by amidation with R 1 R 2 NH to give a compound of the formula (I).
- R a is selected from -OR 1 or -SR 1 when, (I) a compound of formula 2 was prepared according to the following scheme:
- Step 1 Alkaline hydrolysis of ester groups by NaOH with NR 3 -6-(ethoxycarbonyl)-5-R 4 -4-oxo-1,4-dihydropyridine-3-aramidamide (Ig) NR 3 -6-carboxy-5-R 4 -4-oxo-1,4-dihydropyridine-3-aryl amic acid (Ig');
- Step 2 NR 3 -6-carboxy-5-R 4 -4-oxo-1,4-dihydropyridine-3-aryl amic acid (Ig') is reacted with an alcohol or a thiol under the action of EDCI. a compound of formula (I).
- Step 1 NR 3 -3-bromo-4-oxo-1,4-dihydropyridine-2,5-dicarboxylic acid diethyl ester (Id) and substituted aryl boronic acid in Pd(dppf)Cl 2 and Suzuki coupling under the action of K 2 CO 3 , while the substituent amino group, hydroxyl group or sulfhydryl group on the aryl group is cyclized with the ortho ester group to obtain cyclized NR 3 -4-oxo-1,4-di Hydropyridine-5-carboxylate ethyl ester (Ii);
- Step 2 Cyclized NR 3 -4-oxo-1,4-dihydropyridine-5-carboxylate ethyl ester (Ii) is hydrolyzed under basic conditions (NaOH) to give cyclized NR 3 -4-oxyl Des-1,4-dihydropyridin-5-carboxylic acid (Ij);
- Step 3 Cyclization of NR 3 -4-oxo-1,4-dihydropyridine-5-carboxylic acid (Ij) with aromatic amine (Ih) via HATU and N,N-diisopropylethylamine (DIPEA) The amidation reaction is carried out to obtain a compound of the formula (I').
- Step 1 Diethyl 4-oxo-4H-pyran-2,5-dicarboxylate (Ib) with an amino group (-NH 2 ) at one end and an amine with PG-X by addition-condensation Reaction to give N-substituted-4-oxo-1,4-dihydropyridine-2,5-dicarboxylic acid diethyl ester (Ik);
- Step 2 N-substituted 4-oxo-1,4-dihydropyridine-2,5-dicarboxylic acid diethyl ester (Ik) is deprotected and then cyclized with an ortho ester group to obtain a cyclization reaction.
- Step 3 Cyclization of ethyl 4-oxo-1,4-dihydropyridine-5-carboxylate (Il) by bromination of NBS to give cyclized 3-bromo-4-oxo-1,4-di Hydropyridine-5-formic acid ethyl ester (Im);
- Step 4 Cyclization of ethyl 3-bromo-4-oxo-1,4-dihydropyridine-5-carboxylate (Im) with the corresponding boronic acid by Suzuki coupling reaction (potassium carbonate as base, Pd(dppf)Cl 2 is a catalyst, dioxane/water is a mixed solvent, and the reaction temperature is 80 ° C) to obtain a cyclized 3-R 4 -4-oxo-1,4-dihydropyridine-5-carboxylic acid ethyl ester (In );
- Step 5 The cyclized 3-R 4 -4-oxo-1,4-dihydropyridine-5-carboxylic acid ethyl ester intermediate (In) is hydrolyzed under basic conditions (NaOH) to give a cyclized 3- R 4 -4-oxo-1,4-dihydropyridine-5-carboxylic acid intermediate (Io);
- Step 6 Cyclized 3-R 4 -4-oxo-1,4-dihydropyridine-5-carboxylic acid intermediate (Io) with aromatic amine (Ih) via HATU and N,N-diisopropyl B
- the amine (DIPEA) is subjected to an amidation reaction to give a compound of the formula (I").
- Step 1 Diethyl 4-oxo-4H-pyran-2,5-dicarboxylate (Ib) and aminoacetaldehyde dimethylacetal are obtained by addition-condensation reaction to obtain 1-(2,2-dimethoxy Ethyl ethyl)-4-oxo-1,4-dihydropyridine-2,5-dicarboxylic acid diethyl ester (Ip);
- Step 2 1-(2,2-Dimethoxyethyl)-4-oxo-1,4-dihydropyridine-2,5-dicarboxylic acid diethyl ester (Ip) with amino alcohol, amino mercaptan Or the diamine is first subjected to a aldehyde condensation reaction of methanol, and then cyclized with an ortho ester group to obtain a fused ring of ethyl 4-oxo-1,4-dihydropyridine-5-carboxylate (Iq);
- Step 3 The fused ring of ethyl 4-oxo-1,4-dihydropyridine-5-carboxylate (Iq) is brominated by NBS to give the cyclized 3-bromo-4-oxo-1,4-di Hydropyridine-5-formic acid ethyl ester (Ir);
- Step 4 3-bromo-4-oxo-1,4-dihydropyridine-5-carboxylic acid ethyl ester (Ir) and the corresponding boronic acid by Suzuki coupling reaction (potassium carbonate as base, Pd(dppf)Cl 2 as catalyst , dioxane / water is a mixed solvent, the reaction temperature is 80 ° C), to give 3-R 4 -4-oxo-1,4-dihydropyridine-5-carboxylic acid ethyl ester (Is);
- Step 5 Ethyl 3-R 4 -4-oxo-1,4-dihydropyridine-5-carboxylate (Is) is hydrolyzed under basic conditions (NaOH) to give cyclized 3-R 4 -4- Oxo-1,4-dihydropyridine-5-carboxylic acid (It);
- Step 6 Cyclized 3-R 4 -4-oxo-1,4-dihydropyridine-5-carboxylic acid (It) with aromatic amine (Ih) via HATU and N,N-diisopropylethylamine ( DIPEA) is subjected to an amidation reaction to give a compound of the formula (I"').
- R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , W, V, n are as defined in the formula (I).
- Figure 1 Growth curve of tumor volume in treated and control mice in the EBC-1 non-small cell lung cancer model.
- Figure 2 Plot of body weight versus treatment time in treatment and control mice in the EBC-1 non-small cell lung cancer model.
- the compounds of the present invention are prepared using convenient starting materials and common preparatory procedures.
- the present invention provides typical or propensating reaction conditions such as reaction temperature, time, solvent, pressure, molar ratio of reactants. However, other reaction conditions can be adopted unless otherwise stated. Optimization conditions may vary with the use of a particular reactant or solvent, but under normal circumstances, the reaction optimization steps and conditions can be determined.
- protecting groups may be used in the present invention to protect certain functional groups from unwanted reactions.
- protecting groups suitable for the various functional groups and their protection or deprotection conditions are well known to those skilled in the art. For example, T. W. Greene and G. M. Wuts, "Protective Groups in Organic Preparation” (3rd edition, Wiley, New York, 1999, and references cited in the book) describe in detail the protection or deprotection of a large number of protecting groups.
- the separation and purification of the compounds and intermediates are carried out according to specific needs, such as filtration, extraction, distillation, crystallization, column chromatography, preparative thin layer chromatography, preparative high performance liquid chromatography or a mixture of the above methods.
- the specific method of use can be referred to the examples described in the present invention.
- other similar separation and purification methods can be employed. It can be characterized using conventional methods, including physical constants and spectral data.
- the structure of the compound is determined by nuclear magnetic resonance (NMR) or/and mass spectrometry (MS).
- NMR nuclear magnetic resonance
- MS mass spectrometry
- the NMR shift is given in units of 10 -6 (ppm).
- the NMR was determined by using a Brukerdps300 type nuclear magnetic instrument.
- the solvent was deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated chloroform (CDCl 3 ), deuterated methanol (CD 3 OD), and the internal standard was tetramethyl. Silane (TMS).
- the MS was measured using an ACQUITY H-Class UPLC mass spectrometer (QDa Detector) (manufacturer: Waters).
- the liquid phase was prepared using a Waters 2545 High Performance Liquid Chromatograph (Waters 2489 UV/visible Detector, 2767 Sample MGR, Unitary C18, 5 ⁇ m 20 mm x 250 mm) (manufacturer: Waters)
- Thin layer chromatography silica gel plate uses Qingdao Ocean Chemical GF254 silica gel plate.
- the specification of silica gel plate used for thin layer chromatography (TLC) is 0.15mm ⁇ 0.2mm.
- the specification for thin layer chromatography separation and purification is 0.4mm ⁇ 0.5. Mm.
- the known starting materials of the present invention may be synthesized by or according to methods known in the art, or may be purchased from Netcom Mall, Beijing Coupling, Sigma, Belling, Yi Shiming, Shanghai Shuya, Shanghai Inoke, An Nike Chemical, Shanghai Bi De and other companies.
- the reactions can all be carried out under an argon atmosphere or a nitrogen atmosphere.
- An argon atmosphere or a nitrogen atmosphere means that the reaction flask is connected to an argon or nitrogen balloon having a volume of about 1 L.
- the reaction solvent, organic solvent or inert solvent is each expressed as a solvent which does not participate in the reaction under the described reaction conditions, and includes, for example, benzene, toluene, acetonitrile, tetrahydrofuran (THF), dimethylformamide (DMF), chloroform.
- THF tetrahydrofuran
- DMF dimethylformamide
- NMP nitrogen-methylpyrrolidone
- pyridine pyridine
- the chemical reactions described in the present invention are generally carried out under normal pressure.
- the reaction temperature is between -78 ° C and 200 ° C.
- the reaction time and conditions are, for example, one atmosphere, between -78 ° C and 200 ° C, and completed in about 1 to 24 hours. If the reaction is overnight, the reaction time is generally 16 hours. There is no particular description in the examples, and the reaction temperature is room temperature and is 20 ° C to 30 ° C.
- the progress of the reaction in the examples was monitored by thin layer chromatography (TLC).
- TLC thin layer chromatography
- the system used for the reaction was: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: petroleum ether And the ethyl acetate system, D: acetone, the volume ratio of the solvent is adjusted depending on the polarity of the compound.
- the column chromatography eluent system and the thin layer chromatography developer system include: A: dichloromethane and methanol systems, B: n-hexane and ethyl acetate systems, C: petroleum ether and acetic acid
- A dichloromethane and methanol systems
- B n-hexane and ethyl acetate systems
- C petroleum ether and acetic acid
- the volume ratio of the solvent is adjusted depending on the polarity of the compound, and a small amount of an alkaline or acidic reagent such as triethylamine or acetic acid may be added for adjustment.
- ⁇ M micromolar
- DIPEA diisopropylethylamine
- IC 50 concentration that inhibits 50% activity
- NBS N-bromosuccinimide
- PE petroleum ether
- TBDPS tert-butyldiphenyl silicon
- Step 1 Preparation of ethyl (Z)-2-((dimethylamino)methylene)-3-oxobutanoate (a1)
- Step 4 Preparation of 3-bromo-1-methyl-4-oxo-1,4-dihydropyridine-2,5-dicarboxylic acid diethyl ester (a4)
- Step 5 Preparation of diethyl 3-(4-fluorophenyl)-1-methyl-4-oxo-1,4-dihydropyridine-2,5-dicarboxylate (a5)
- Step 6 Preparation of 6-(ethoxycarbonyl)-5-(4-fluorophenyl)-1-methyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid (a)
- 5-(4-fluorophenyl)-4 was obtained in the same manner as in Preparation Example 1, except that (tetrahydro-2H-pyran-4-yl)methanamine (Shanghai Pide) was used instead of the aqueous methylamine solution.
- -oxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-1,4-dihydropyridine-3-carboxylic acid (c) (white solid, four-step yield: 36.8%)
- Step 2 Preparation of 1-(3-aminopropyl)-4-oxo-1,4-dihydropyridine-2,5-dicarboxylic acid ethyl ester hydrochloride (d2)
- Step 4 10-Bromo-1,9-dioxo-1,2,3,4,5,9-hexahydropyrido[1,2-a][1,4]diazepane- Preparation of 8-carboxylic acid ethyl ester (d4)
- Step 5 10-(4-Fluorophenyl)-1,9-dioxo-1,2,3,4,5,9-hexahydropyrido[1,2-a][1,4] Preparation of azacycloheptane-8-carboxylic acid ethyl ester (d5)
- 1,3-Diamino-2-hydroxypropane (4 g, 44.4 mmol) and imidazole (6.1 g, 88.8 mmol) were added to a round bottom flask containing DMF (30 mL) at room temperature.
- the mixture was cooled to 0 ° C, and a solution of TBDPSCl in DMF (30 mL, 88.8 mmol) was slowly added dropwise. After the addition was completed, the temperature was raised to room temperature and stirred overnight. After the reaction was completed, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting elut elut elut elut elut 12.4 g, yellow oil, yield 85.1%).
- Step 2 4-((tert-Butyldiphenylsilyl)oxy)-1,9-dioxo-1,2,3,4,5,9-hexahydropyrido[1,2- Preparation of a][1,4]diazepane-8-carboxylic acid ethyl ester (f2)
- Step 3 10-Bromo-4-((tert-butyldiphenylsilyl)oxy)-1,9-dioxo-1,2,3,4,5,9-hexahydropyridyl[ Preparation of 1,2-a][1,4]diazepane-8-carboxylic acid ethyl ester (f3)
- Step 4 4-((tert-Butyldiphenylsilyl)oxy)-10-(4-fluorophenyl)-1,9-dioxo-1,2,3,4,5,9 -Preparation of ethyl hexahydropyrido[1,2-a][1,4]diazepane-8-carboxylate (f4)
- Step 5 10-(4-Fluorophenyl)-4-hydroxy-1,9-dioxo-1,2,3,4,5,9-hexahydropyrido[1,2-a][1 , 4] Preparation of diazepane-8-carboxylic acid (f)
- Step 1 1 - ((1-(tert-Butoxycarbonyl)piperidin-2-yl)methyl)-4-oxo-1,4-dihydropyridine-2,5-dicarboxylic acid diethyl ester ( Preparation of g1)
- Step 3 Preparation of 3-bromo-4-oxo-1-(piperidin-2-ylmethyl)-1,4-dihydropyridine-2,5-dicarboxylic acid diethyl ester hydrochloride (g3)
- Step 4 1-Bromo-2,12-dioxo-2,6,6a,7,8,9,10,12-octahydrodipyrido[1,2-a:1',2'-d Preparation of pyrazine-3-carboxylic acid ethyl ester (g4)
- Step 5 1-(4-Fluorophenyl)-2,12-dioxo-2,6,6a,7,8,9,10,12-octahydrodipyrido[1,2-a:1 Preparation of ',2'-d]pyrazine-3-carboxylic acid ethyl ester (g5)
- Step 6 1-(4-Fluorophenyl)-2,12-dioxo-2,6,6a,7,8,9,10,12-octahydrodipyrido[1,2-a:1 Preparation of ',2'-d]pyrazine-3-carboxylic acid (g)
- Morpholine-3-carboxylic acid (3.0 g, 22.9 mmol) and potassium carbonate (15.8 g, 114.4 mmol) were added to a round bottom flask containing acetone (20 mL) and water (10 mL). Boc 2 O (7.5 g, 34.4 mmol) was slowly added dropwise with stirring, and the mixture was stirred at this temperature overnight. After the reaction was completed, the reaction mixture was concentrated under reduced pressure. The residue was purified by EtOAc EtOAc EtOAc EtOAc EtOAc : 34.1%).
- Step 2 Preparation of 3-carbamoylmorpholine-4-carboxylic acid tert-butyl ester (j1-2)
- Step 3 Preparation of 3-(aminomethyl)morpholine-4-carboxylic acid tert-butyl ester (j1)
- PREPARATIVE EXAMPLE 10 7-(4-Fluorophenyl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4 ,5]Preparation of pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid (intermediate k)
- Step 2 Preparation of 3-bromo-1-(2,2-dimethoxyethyl)-4-oxo-1,4-dihydropyridine-2,5-dicarboxylic acid diethyl ester (k2)
- Step 4 7-(4-Fluorophenyl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5
- pyrazino[2,1-B][1,3]oxazine-9-carboxylic acid ethyl ester k4
- Step 5 7-(4-Fluorophenyl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5
- PREPARATIVE EXAMPLE 12 7-(6-Methylpyridin-3-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1', Preparation of 2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid (intermediate m)
- PREPARATIVE EXAMPLE 13 7-(5-Methylthiophen-2-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1', Preparation of 2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid (intermediate n)
- PREPARATIVE EXAMPLE 16 (3R)-6-(4-Fluorophenyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazole[ Preparation of 3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid (intermediate q)
- PREPARATIVE EXAMPLE 17 (3S)-6-(4-Fluorophenyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazole[ Preparation of 3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid (intermediate r)
- PREPARATIVE EXAMPLE 18 (4R)-7-(4-Fluorophenyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyridine And [1', 2': 4,5] Preparation of pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid (intermediate s)
- Step 2 Preparation of tert-butyl 4-(4-(6-amino-5-bromopyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (u2)
- Step 1 Preparation of 4-((4-bromo-2-methoxyphenoxy)methyl)-2,2-dimethyl-1,3-dioxolan (bb1)
- 3-(4-Bromo-2-methoxyphenoxy)propane-1,2-diol (2.1 g, 7.58 mmol) was added sequentially to a reaction flask containing 1,2-dibromoethane (30 mL). Tetrabutylammonium bromide (488 mg, 1.52 mmol) and 50% (w/w) sodium hydroxide solution (30 mL). After heating the mixture to 55 ° C and stirring for 6 hours, additional 1,2-dibromoethane (30 mL) and 50% (w/w) sodium hydroxide solution (30 mL) were added and stirring was continued at this temperature overnight. .
- reaction solution was cooled to room temperature, it was diluted with water and extracted with dichloromethane (100 mL x 3), and the organic phase was combined. The organic layer was washed with brine, dried over anhydrous sodium sulfate The residue was purified by silica gel column chromatography (EtOAc:EtOAc: Dioxane (1.7 g, yellow solid, yield: 73.9%).
- Step 4 2-(4-((1,4-Dioxa-2-yl)methoxy)-3-methoxyphenyl)-4,4,5,5-tetramethyl-1, Preparation of 3,2-dioxaborane (bb4)
- Step 6 5-(4-((1,4-Dioxa-2-yl)methoxy)-3-methoxyphenyl)-3-(4-amino-2-fluorophenyl)pyridine
- Step 2 4-((2-(4-Bromo-2-methoxyphenoxy)ethoxy)methyl)-2,2-dimethyl-1,3-dioxolane (cc) Preparation
- Step 1 Preparation of 4-(2-(4-bromo-2-methoxyphenoxy)ethyl)morpholine (ee1-1)
- Step 2 4-(2-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy) Preparation of ethyl)ethyl)morpholine (ee1)
- Step 1 4-(((2,2-Dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl)amino)-2-methoxybenzene Preparation of methyl formate (hh1)
- Methyl 4-amino-2-methoxybenzoate (5 g, 27.6 mmol) was added to a reaction flask containing isopropyl alcohol (100 mL) at room temperature. The mixture was warmed to 50 ° C and stirred for 10 minutes, then added 5-(methoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (Shanghai Bi De , 5.13 g, 27.6 mmol). The mixture was further heated to 80 ° C and stirred for 1 hour.
- Step 3 Preparation of 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-(2-methoxyethoxy)quinazoline (oo3)
- Step 4 Preparation of 3-fluoro-4-((6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl)oxy)phenylamine (oo)
- PREPARATIVE EXAMPLE 42 4-(2-((4-(4-Amino-2-fluorophenoxy)-6-methoxyquinazolin-7-yl)oxy)ethyl)piperazine-1 -Preparation of tert-butyl formate (intermediate qq)
- Step 1 5-((4-(2-Amino-5-(1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyridine-3- Ethyl 3-fluorophenyl)carbamoyl)-3-(4-fluorophenyl)-1-methyl-4-oxo-1,4-dihydropyridine-2-carboxylate (1a)
- Step 2 5-((4-(2-Amino-5-(1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyridine-3- Of 3-(fluorophenyl)carbamoyl)-3-(4-fluorophenyl)-1-methyl-4-oxo-1,4-dihydropyridine-2-carboxylic acid (1b)
- Step 3 4-(4-(6-Amino-5-(4-(6-carbamoyl-5-(4-fluorophenyl)-1-methyl-4-oxo-1,4-di) Preparation of tert-butyl ester (1c) of hydropyridine-3-carboxamido)-2-fluorophenyl)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate
- Step 4 N 5 -(4-(2-Amino-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-3-fluorophenyl) Preparation of -3-(4-fluorophenyl)-1-methyl-4-oxo-1,4-dihydropyridine-2,5-dimethylformamide (1)
- Example 2 The same procedure as in Example 1 was carried out except that 5-(4-fluorophenyl)-4-oxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-1,4- Dihydropyridine-3-carboxylic acid (c) in place of 6-(ethoxycarbonyl)-5-(4-fluorophenyl)-1-methyl-4-oxo-1,4-dihydropyridine-3- Carboxylic acid (a) to give N 5 -(4-(2-amino-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-3 -fluorophenyl)-3-(4-fluorophenyl)-4-oxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-1,4-dihydropyridine-2 , 5-dimethylformamide (7) (white solid, four-step yield: 11.2%).
- Step 1 4-oxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-1,4-dihydropyridine-2,5-dicarboxylic acid diethyl ester (9a) preparation
- Step 4 5-((4-(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)phenyl)carbamoyl)-3-bromo-4-oxo
- Step 5 5-((4-(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)phenyl)carbamoyl)-4-oxo-1-( Preparation of ethyl (tetrahydro-2H-pyran-4-yl)methyl)-3-(p-tolyl)-1,4-dihydropyridine-2-carboxylate (9e)
- Step 6 5-((4-(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)phenyl)carbamoyl)-4-oxo-1-( Preparation of (tetrahydro-2H-pyran-4-yl)methyl)-3-(p-tolyl)-1,4-dihydropyridine-2-carboxylic acid (9f)
- Step 7 N 5 -(4-(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)phenyl)-N 2 -methyl-4-oxo-1
- Step 7 N 5 -(4-(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)phenyl)-N 2 -methyl-4-oxo-1
- Example 10 N 5 -(4-(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)-3-fluorophenyl)-3-(4-fluorobenzene Of 1-(1-isopropyl-4-oxo-1,4-dihydropyridine-2,5-dimethylformamide (10)
- Example 10 The same procedure as in Example 10 was employed except that 6-(ethoxycarbonyl)-5-(4-fluorophenyl)-1-methyl-4-oxo-1,4-dihydropyridine-3-
- the carboxylic acid (a) is substituted for 5-(4-fluorophenyl)-1-isopropyl-4-oxo-1,4-dihydropyridine-3-carboxylic acid (b) to obtain N 5 -(4- (2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)-3-fluorophenyl)-3-(4-fluorophenyl)-1-methyl-4- Oxo-1,4-dihydropyridine-2,5-dimethylformamide (11) (white solid, three-step yield: 18.8%).
- Example 11 The same procedure as in Example 11 was employed except that 3-(4-amino-2-fluorophenyl)-5-(1-ethyl-1H-pyrazol-4-yl)pyridin-2-amine (v) was used. Instead of 3-(4-amino-2-fluorophenyl)-5-(3,4-dimethoxyphenyl)pyridin-2-amine (x), N 5 -(4-(2-amino) was obtained.
- Example 13 N 5 -(4-(2-Amino-5-(1-ethyl-1H-pyrazol-4-yl)pyridin-3-yl)-3-fluorophenyl)-3-(4 Of -fluorophenyl)-1-isopropyl-4-oxo-1,4-dihydropyridine-2,5-dimethylformamide (13)
- Example 14 N-(4-(2-Amino-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-3-fluorophenyl) -10-(4-fluorophenyl)-1,9-dioxo-1,2,3,4,5,9 hexahydropyrido[1,2- ⁇ ][1,4]diazepine Preparation of heptane-8-carboxamide (14)
- Step 1 4-(4-(6-Amino-5-(2-fluoro-4-(10-(4-fluorophenyl)-1,9-dioxo-1,2,3,4,5 ,9-Hexidopyrido[1,2- ⁇ ][1,4]diazepane-8-formylamino)phenyl)pyridin-3-yl)-1H-pyrazol-1-yl
- piperidine-1-carboxylic acid tert-butyl ester 14a
- Step 2 N-(4-(2-Amino-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-3-fluorophenyl)- 10-(4-fluorophenyl)-1,9-dioxo-1,2,3,4,5,9-hexahydropyrido[1,2- ⁇ ][1,4]diazepine
- Example 14 The same procedure as in Example 14 was employed except that 4-(4-(6-amino-5-(4-amino-2,5-difluorophenyl)pyridin-3-yl)-1H-pyrazole-1 was used.
- Example 16 N-(4-(2-Amino-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-3-fluorophenyl) -7-(4-fluorophenyl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-pyrido[1',2':4,5]pyridyl Preparation of oxazolo[2,1-C][1,4]oxazine-9-carboxamide (16)
- Example 14 The same procedure as in Example 14 was carried out except that 7-(4-fluorophenyl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-pyrido[1] was used.
- Example 14 The same procedure as in Example 14 was carried out except that 7-(4-fluorophenyl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1] was used.
- Example 14 The same procedure as in Example 14 was carried out except that 6,8-dioxy-7-(p-tolyl)-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2 was used.
- Example 20 N-(4-(2-Amino-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-3-fluorophenyl) -10-(4-fluorophenyl)-4-hydroxy-1,9-dioxo-1,2,3,4,5,9-hexahydropyrido[1,2- ⁇ ][1,4 Preparation of diazepane-8-carboxamide (20)
- Example 14 The same procedure as in Example 14 was carried out except that 10-(4-fluorophenyl)-4-hydroxy-1,9-dioxo-1,2,3,4,5,9-hexahydropyridyl[ 1,2-a][1,4]diazepane-8-carboxylic acid (f) instead of 10-(4-fluorophenyl)-1,9-dioxo-1,2,3,4 ,5,9-hexahydropyrido[1,2-a][1,4]diazepane-8-carboxylic acid (d), to give N-(4-(2-amino-5-( 1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-3-fluorophenyl)-10-(4-fluorophenyl)-4-hydroxy-1, 9-dioxo 1,2,3,4,5,9 hexahydropyrido[1,2- ⁇ ][1,4]diazepane
- Example 14 The same procedure as in Example 14 was employed except that (4R)-7-(4-fluorophenyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a- Hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid (s) in place of 10-(4-fluorobenzene) -1,9-dioxo-1,2,3,4,5,9-hexahydropyrido[1,2-a][1,4]diazepane-8-carboxylic acid ( d), (4R)-N-(4-(2-amino-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-3 -fluorophenyl)-7-(4-fluorophenyl)-4-methyl-6,8-dioxo-3,4,6,8,12
- Example 23 N-(4-(2-Amino-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-3-fluorophenyl) -6-(4-fluorophenyl)-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2- d] Preparation of pyrazine-8-carboxamide (23)
- Example 14 The same procedure as in Example 14 was carried out except that 6-(4-fluorophenyl)-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazole [3,2 -a]pyrido[1,2-d]pyrazine-8-carboxylic acid (o) instead of 10-(4-fluorophenyl)-1,9-dioxo-1,2,3,4,5 , 9-hexahydropyrido[1,2-a][1,4]diazepan-8-carboxylic acid (d), to obtain N-(4-(2-amino-5-(1-) (piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-3-fluorophenyl)-6-(4-fluorophenyl)-5,7-dioxo- 2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido
- Example 24 (3R)-N-(4-(2-Amino-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-3- Fluorophenyl)-6-(4-fluorophenyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazole[3,2- Preparation of a] pyrido[1,2-d]pyrazine-8-carboxamide (24)
- Example 25 N-(4-(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)-3-fluorophenyl)-6-(4-fluorophenyl) )-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide Preparation of (25)
- Example 23 The same procedure as in Example 23 was carried out except that 3-(4-amino-2-fluorophenyl)-5-(3,4-dimethoxyphenyl)pyridin-2-amine (x) was used instead of 4- (4-(6-Amino-5-(4-amino-2-fluorophenyl)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid tert-butyl ester (u), Preparation of N-(4-(2-amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)-3-fluorophenyl)-6-(4-fluorophenyl)- 5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide (25 (white solid, one step yield: 40.2%).
- Example 26 N-(4-(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)-3-fluorophenyl)-10-(4-fluorophenyl) -1,9-dioxo-1,2,3,4,5,9-hexahydropyrido[1,2- ⁇ ][1,4]diazepane-8-carboxamide ( Preparation of 26)
- Example 27 N-(4-(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)phenyl)-1,9-dioxo-10-(pair Of -tolyl)-1,2,3,4,5,9-hexahydropyrido[1,2- ⁇ ][1,4]diazepane-8-carboxamide (27)
- Example 19 The same procedure as in Example 19 was carried out except that 3-(4-amino-2-methylphenyl)-5-(3,4-dimethoxyphenyl)pyridin-2-amine (aa) was used instead of 4-( 4-(6-Amino-5-(4-amino-2-fluorophenyl)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid tert-butyl ester (u), made N-(4-(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)phenyl)-1,9-dioxo-10-(p-tolyl) -1,2,3,4,5,9-hexahydropyrido[1,2- ⁇ ][1,4]diazepane-8-carboxamide (27) (white solid, one step Rate: 37.9%).
- Example 27 The same procedure as in Example 27 was employed except that (3R)-6-(4-fluorophenyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a- Instead of 1,9-dioxo-10-(p-tolyl)-1, hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid (q) 2,3,4,5,9-Hexidopyrido[1,2-a][1,4]diazepane-8-carboxylic acid (e), (3R)-N-(4) -(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)phenyl)-6-(4-fluorophenyl)-3-methyl-5,7-di Oxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8
- Example 28 The same procedure as in Example 28 was employed except that (3S)-6-(4-fluorophenyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a- Hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid (r) in place of 1,9-dioxo-10-(p-tolyl)-1, 2,3,4,5,9-hexahydropyrido[1,2-a][1,4]diazepane-8-carboxylic acid (e), (3S)-N-(4) -(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)phenyl)-6-(4-fluorophenyl)-3-methyl-5,7-di Oxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8
- Example 30 N-(4-(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)-2,5-difluorophenyl)-6-(4- Fluorophenyl)-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8 - Preparation of formamide (30)
- Step 1 Preparation of 3-(4-amino-2,5-difluorophenyl)-5-(3,4-dimethoxyphenyl)pyridin-2-amine (Intermediate 30a)
- 3-bromo-5-(3,4-dimethoxyphenyl)pyridine was added to a reaction flask containing (10 mL) a mixture of 1,4-dioxane and water (4:1) at room temperature.
- 2-Amine prepared according to Example 30 of WO2013115280, page 130) (500 mg, 1.62 mmol), 4-amino-2,5-difluorophenylboronic acid pinacol ester (619 mg, 2.43 mmol), potassium carbonate (671 mg, 4.86 mmol), Pd(dppf)Cl 2 .DCM (130 mg, 0.16 mmol). Sealed, replaced with nitrogen three times, heated to 90 ° C and stirred overnight.
- Step 2 N-(4-(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)-2,5-difluorophenyl)-6-(4-fluoro Phenyl)-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8- Preparation of formamide (30)
- Example 31 N-(4-(2-Amino-5-(1-ethyl-1H-pyrazol-4-yl)pyridin-3-yl)-3-fluorophenyl)-6-(4- Fluorophenyl)-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8 - Preparation of formamide (31)
- Example 30 The same procedure as in Example 30 was employed except that 3-(4-amino-2-fluorophenyl)-5-(1-ethyl-1H-pyrazol-4-yl)pyridin-2-amine (v) Instead of 3-(4-amino-2,5-difluorophenyl)-5-(3,4-dimethoxyphenyl)pyridin-2-amine (30a), N-(4-(2) was obtained.
- Example 31 The same procedure as in Example 31 was carried out except that 10-(4-fluorophenyl)-4-hydroxy-1,9-dioxo-1,2,3,4,5,9-hexahydropyridyl[ 1,2-a][1,4]diazepane-8-carboxylic acid (f) in place of 6-(4-fluorophenyl)-5,7-dioxo-2,3,5,7 ,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid (o), N-(4-(2-amino-5) -(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)-3-fluorophenyl)-10-(4-fluorophenyl)-4-hydroxy-1-,9-di Oxo-1,2,3,4,5,9-hexahydropyrido[1,2-a][1,4]diazepan
- Example 35 N-(4-(2-Amino-5-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)phenyl -1,9-dioxo-10-(p-tolyl)-1,2,3,4,5,9-hexahydropyrido[1,2-a][1,4]diazacyclocycle Preparation of heptane-8-carboxamide (35)
- Example 36 N-(4-(2-Amino-5-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-3 -fluorophenyl)-1,9-dioxo-10-(p-tolyl)-1,2,3,4,5,9-hexahydropyrido[1,2-a][1,4] Preparation of diazepane-8-carboxamide (36)
- Example 37 N-(4-(2-Amino-5-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-3 -fluorophenyl)-7-(6-methylpyridin-3-yl)-6,8-dioxo 3,4,6,8,12,12a-hexahydro-2H-pyrido[1', Preparation of 2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide (37)
- Example 36 The same procedure as in Example 36 was employed except that 7-(6-methylpyridin-3-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H- Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid (m) instead of 1,9-dioxo-10-(pair Tolyl-1,2,3,4,5,9-hexahydropyrido[1,2-a][1,4]diazepane-8-carboxylic acid (e), to give N- (4-(2-Amino-5-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-3-fluorophenyl)- 7-(6-Methylpyridin-3-yl)-6,8-dioxo-3,4,6,8,12,12a-hex
- Example 14 The same procedure as in Example 14 was employed except that 3-(4-amino-2-fluorophenyl)-5-(3-methoxy-4-(2-morpholinoethoxy)phenyl)pyridine- 2-amine (ee) instead of 4-(4-(6-amino-5-(4-amino-2-fluorophenyl)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1 - tert-butyl formate (u) to give N-(4-(2-amino-5-(3-methoxy-4-(2-morpholinoethoxy)phenyl)pyridin-3-yl) 3-fluorophenyl)-10-(4-fluorophenyl)-1,9-dioxo-1,2,3,4,5,9-hexahydropyrido[1,2-a][ 1,4]diazepane-8-carboxamide (38) (white solid, one step yield: 21.3%).
- Example 39 N-(4-(2-Amino-5-(3-methoxy-4-(2-morpholinoethoxy)phenyl)pyridin-3-yl)-3-fluorophenyl) -7-(5-methylthiophen-2-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4 ,5]Preparation of pyrazino[2,1-b][1,3]oxazine-9-carboxamide (39)
- Example 38 The same procedure as in Example 38 was employed except for 7-(5-methylthiophen-2-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyridine.
- Example 40 N-(4-(5-(4-(2-((1,4-dioxo)-2-yl)methoxy)ethoxy)-3-methoxyphenyl)- 2-amino-pyridin-3-yl)-3-fluorophenyl)-6-(4-fluorophenyl)-5,7-dioxo-2,3,5,7,11,11a-hexahydro Preparation of oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide (40)
- Example 38 The same procedure as in Example 38 was carried out except that 6-(4-methylphenyl)-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a ] Pyrido[1,2-d]pyrazine-8-carboxylic acid (p) in place of 10-(4-fluorophenyl)-1,9-dioxo-1,2,3,4,5,9 -Hexidopyrido[1,2-a][1,4]diazepan-8-carboxylic acid (d) to give N-(4-(2-amino-5-(3-methoxy) 4-(2-morpholinoethoxy)phenyl)pyridin-3-yl)-3-fluorophenyl)-5,7-dioxo-6-(p-tolyl)-2,3, 5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazin
- Example 42 N-(4-(5-(4-(4-1,4-dioxan-2-yl)methoxy)-3-methoxyphenyl)-2-amino-pyridine-3 -yl)-3-fluorophenyl)-6-(4-fluorophenyl)-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazole[3,2 -a]Preparation of pyrido[1,2-d]pyrazine-8-carboxamide (42)
- Example 41 The same procedure as in Example 41 was carried out except that 6,8-dioxo-7-(p-tolyl)-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2 ':4,5]pyrazine[2,1-b][1,3]oxazine-9-carboxylic acid (l) instead of 6-(4-methylphenyl)-5,7-dioxo-2, 3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid (p) to give N-(4-( 2-Amino-5-(3-methoxy-4-(2-morpholinoethoxy)phenyl)pyridin-3-yl)-3-fluorophenyl)-6,8-dioxo-7 -(p-tolyl)-3,4,6,8,12,12a-hexahydro-2H-pyrido
- Example 44 N-(4-(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)phenyl)-1,5-dioxo-4-(( Preparation of tetrahydro-2H-pyran-4-yl)methyl)-1,4,5,6-tetrahydrobenzo[f][1,7]naphthyridin-2-carboxamide (44)
- Step 1 N-(4-(2-Amino-5-(3,4-dimethoxyphenyl)pyridin-3-yl)phenyl)-1,5-dioxo-4-((four Preparation of hydrogen-2H-pyran-4-yl)methyl)-1,4,5,6-tetrahydrobenzo[f][1,7]naphthyridin-2-carboxamide (44)
- Step 2 5-((4-(2-Amino-5-(1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyridine-3- 3-fluorophenyl)carbamoyl)-3-bromo-4-oxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-1,4-dihydropyridine
- ethyl-2-carboxylate 45b
- Step 3 4-(4-(6-Amino-5-(2-fluoro-4-(8-fluoro-1,5-dioxo-4-((tetrahydro-2H-pyran-4-yl)) [Methyl)-1,4,5,6-tetrahydrobenzo[f][1,7]naphthyridin-2-carboxamido)phenyl)pyridin-3-yl)-1H-pyrazole- Preparation of tert-butyl ester of 1-yl) piperidine-1-carboxylate (45c)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un dérivé de pyridone polysubstitué, son procédé de préparation et son utilisation médicale. En particulier, la présente invention concerne un dérivé de pyridone polysubstitué de formule générale (I), un procédé de préparation de celui-ci, une composition pharmaceutique le contenant, et l'utilisation de celui-ci en tant qu'inhibiteur de Axl/c-MET dans le traitement de cancers, les définitions de chaque groupe dans la formule générale (I) étant les mêmes que celles données dans la description.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880024273.6A CN110520416B (zh) | 2017-10-26 | 2018-10-12 | 多取代吡啶酮类衍生物、其制备方法及其医药用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711011780.X | 2017-10-26 | ||
CN201711011780 | 2017-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019080723A1 true WO2019080723A1 (fr) | 2019-05-02 |
Family
ID=66246754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/109969 WO2019080723A1 (fr) | 2017-10-26 | 2018-10-12 | Dérivé de pyridone polysubstitué, son procédé de préparation et son utilisation médicale |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110520416B (fr) |
WO (1) | WO2019080723A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111233779A (zh) * | 2020-04-02 | 2020-06-05 | 廖文英 | 一种来氟米特的制备方法 |
WO2021057782A1 (fr) * | 2019-09-24 | 2021-04-01 | 南京药捷安康生物科技有限公司 | Dérivé hétérocyclique et utilisation associée |
CN112625026A (zh) * | 2019-09-24 | 2021-04-09 | 南京药捷安康生物科技有限公司 | Tam家族激酶抑制剂的喹啉衍生物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113527332B (zh) * | 2020-04-13 | 2022-07-26 | 南开大学 | 具有生物活性的卡波特韦衍生物及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011095045A1 (fr) * | 2010-02-03 | 2011-08-11 | 上海源力生物技术有限公司 | Dérivés amides de pyridinone, leurs procédés de préparation et leurs utilisations médicales |
WO2012006960A1 (fr) * | 2010-07-14 | 2012-01-19 | Zhejiang Beta Pharma Inc. | Nouveaux dérivés hétérocycliques fusionnés convenant comme inhibiteurs de c-met tyrosine kinase |
WO2012059041A1 (fr) * | 2010-11-02 | 2012-05-10 | Centaurus Biopharma Co., Ltd. | Nouveaux 6-arylaminopyridonecarboxamides comme inhibiteurs de mek |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2359836T3 (es) * | 2004-04-23 | 2011-05-27 | Bristol-Myers Squibb Company | Heterociclos monociclicos como inhibidores de quinasa. |
CN1993130B (zh) * | 2004-06-28 | 2010-06-23 | 布里斯托尔-迈尔斯斯奎布公司 | 用于制备稠合杂环激酶抑制剂的方法和中间体 |
-
2018
- 2018-10-12 CN CN201880024273.6A patent/CN110520416B/zh active Active
- 2018-10-12 WO PCT/CN2018/109969 patent/WO2019080723A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011095045A1 (fr) * | 2010-02-03 | 2011-08-11 | 上海源力生物技术有限公司 | Dérivés amides de pyridinone, leurs procédés de préparation et leurs utilisations médicales |
WO2012006960A1 (fr) * | 2010-07-14 | 2012-01-19 | Zhejiang Beta Pharma Inc. | Nouveaux dérivés hétérocycliques fusionnés convenant comme inhibiteurs de c-met tyrosine kinase |
WO2012059041A1 (fr) * | 2010-11-02 | 2012-05-10 | Centaurus Biopharma Co., Ltd. | Nouveaux 6-arylaminopyridonecarboxamides comme inhibiteurs de mek |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021057782A1 (fr) * | 2019-09-24 | 2021-04-01 | 南京药捷安康生物科技有限公司 | Dérivé hétérocyclique et utilisation associée |
CN112625026A (zh) * | 2019-09-24 | 2021-04-09 | 南京药捷安康生物科技有限公司 | Tam家族激酶抑制剂的喹啉衍生物 |
CN112625027A (zh) * | 2019-09-24 | 2021-04-09 | 南京药捷安康生物科技有限公司 | 杂环衍生物及其用途 |
CN112625026B (zh) * | 2019-09-24 | 2022-09-09 | 药捷安康(南京)科技股份有限公司 | Tam家族激酶抑制剂的喹啉衍生物 |
CN111233779A (zh) * | 2020-04-02 | 2020-06-05 | 廖文英 | 一种来氟米特的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110520416A (zh) | 2019-11-29 |
CN110520416B (zh) | 2022-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI719437B (zh) | Mat2a之雜雙環抑制劑及治療癌症之使用方法 | |
WO2020239077A1 (fr) | Régulateur dérivé hétérocyclique contenant de l'azote, son procédé de préparation et son application | |
JP6771464B2 (ja) | Cbpおよび/またはep300インヒビターとしての、4,5,6,7−テトラヒドロ−1h−ピラゾロ[4,3−c]ピリジン−3−アミン化合物 | |
JP2020183397A (ja) | Btk活性阻害剤としてのヘテロアリールピリドン及びアザピリドン化合物 | |
JP2019081786A (ja) | Trkaキナーゼ阻害剤としてのn−ピロリジニル、n’−ピラゾリル尿素、チオ尿素、グアニジン、およびシアノグアニジン化合物 | |
CN108137593B (zh) | 蛋白激酶抑制剂的制备和用途 | |
CA3121236A1 (fr) | Derives de 2-oxoquinazoline utilises en tant qu'inhibiteurs de la methionine adenosyltransferase 2a | |
WO2020073945A1 (fr) | Inhibiteur de dérivé bicyclique, son procédé de préparation et son utilisation | |
CN110520416B (zh) | 多取代吡啶酮类衍生物、其制备方法及其医药用途 | |
WO2021143701A1 (fr) | Composé hétérocyclique de pyrimidine-4(3h)-cétone, son procédé de préparation et son utilisation en médecine et en pharmacologie | |
CN113195471B (zh) | 多取代吡啶酮类衍生物及其在医药上的应用 | |
US20230322803A1 (en) | Substituted oxoisoindoline compounds for the treatment of cancer | |
TWI601724B (zh) | 咪唑並喹啉類衍生物及其可藥用鹽、其製備方法及其在醫藥上的應用 | |
CN115956080A (zh) | 双环化合物,包含其的组合物及其应用 | |
CN112292378A (zh) | 含吲哚类衍生物抑制剂、其制备方法和应用 | |
TW202116753A (zh) | 以噌啉作為hpk1的抑制劑 | |
WO2015058661A1 (fr) | Inhibiteur de bcr-abl kinase et application correspondante | |
JP2020503321A (ja) | キナゾリン化合物並びにその調製方法、使用及び医薬組成物 | |
TW202204351A (zh) | 具有大環結構的化合物及其用途 | |
WO2020221209A1 (fr) | Inhibiteur de cd73, son procédé de préparation et son utilisation | |
WO2023036252A1 (fr) | Dérivé de pyrrolopyrimidine ou de pyrrolopyridine et son utilisation médicale | |
WO2015014283A1 (fr) | Inhibiteur de protéine tyrosine kinase et application associée | |
WO2022063050A1 (fr) | Composé pyrazole et son procédé de préparation et son utilisation | |
TW202214634A (zh) | 雜環化合物及其衍生物 | |
WO2022161447A1 (fr) | Composé dicarboxamide, son procédé de préparation et son utilisation pharmaceutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18869839 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18869839 Country of ref document: EP Kind code of ref document: A1 |